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THE BURGEONING “BIORIGHTS 
MOVEMENT”: ITS LEGAL BASIS, WHAT’S 
AT STAKE, AND HOW TO RESPOND 
Abstract: The advent of genetic and genomic technologies has the power to 
transform the understanding, prevention, and treatment of disease on a scale un-
precedented in modern medicine. The promise of the era of precision medicine 
risks being tempered by the emergence of what is increasingly being referred to 
as the “biorights movement.” Of particular concern is the growing trend of indi-
viduals refusing to contribute their biological material to research studies absent 
some form of monetary compensation. Recently announced, but yet to be imple-
mented, regulations seek to mitigate some of the potentially harmful and pro-
gress-impeding positions advanced by the biorights movement. The proposed 
changes to the legal and regulatory framework, however, do not sufficiently ad-
dress the opportunities and challenges of the rapidly evolving patient-consumer 
landscape as it relates to personal genetic testing. Never before have patients 
been able to know so much about their genetic profile and the potentially valua-
ble information their DNA contains from both a research and commercial per-
spective. Bolstered by numerous public policy justifications, this Note argues 
that legislative action needs to be taken that proscribes the ability of individuals 
to sell their biological material for research purposes. 
INTRODUCTION 
Medical research in the United States has long been predicated on the ac-
cess to and use of human biological samples collected in the course of clinical 
care.1 Individuals can contribute their biological materials through participa-
tion in formal research projects with informed consent procedures.2 Addition-
ally, researchers collect blood, tumor pieces, or tissue that would otherwise be 
discarded as medical waste following a medical or surgical procedure.3 Sam-
ples collected in this manner do not typically require informed consent; how-
ever, many institutional consent forms for diagnostic or surgical procedures 
                                                                                                                           
 1 Rina Hakimian & David Korn, Ownership and Use of Tissue Specimens for Research, 292 J. 
AM. MED. ASS’N 2500, 2503 (2004). Until the advent of advanced genetic technologies and increased 
concerns about genetic privacy, contributions of biological materials for research were considered to 
advance the public interest. Id. Neither the existence nor the use of large sample archives created 
through altruistic contributions from patients was a matter of public concern or notice. Id. 
 2 Id. at 2501. 
 3 See id. (noting that hospitals and physicians typically use “extra” or “remaining” portions of 
excised specimens for research). 
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include language permitting the institution’s use of any extra or remaining bio-
logical materials for unspecified future research purposes.4 
Recent developments in what is being increasingly referred to as the “bio-
rights movement” have prompted consideration at the local, state, and federal 
government levels of whether current collection and consent practices should 
be permitted to continue.5 Of particular concern is the growing trend of indi-
viduals refusing to contribute their biological material for research absent 
some form of compensation.6 At stake is the continued progress of medical 
                                                                                                                           
 4 Id. 
 5 See Beth Daley & Ellen Cranley, ‘Biorights’ Rise: Donors Demand Control of Their Samples, BOS. 
GLOBE (Oct. 10, 2016), https://www.bostonglobe.com/metro/2016/10/09/the-rise-biorights-donors-are-
demanding-control-and-sometimes-cash-exchange-for-genetic-samples/jCbaQ2E5t6c0Qs1kcITMRM/
story.html [https://perma.cc/55PB-57UT] (describing how patients are asserting rights to their biolog-
ical material collected in the course of medical treatment). For example, a Boston-area woman suffer-
ing from a potentially fatal heart condition refused to provide a blood or saliva sample to medical 
researchers who would not in exchange promise her the results of their work or offer compensation for 
her sample. Id. The patient, instead, gave the sample to a medical start-up company, DNASimple, that 
offered her $50 for a saliva sample and additional compensation for any future samples needed. Id. 
The patient was quoted as saying, “Innovation and progress will save lives eventually, but there has 
been an over-assumption and a gross expectation of patient altruism.” Id. DNASimple was founded in 
2015 and has signed up almost four thousand people to date. Id. The startup promotes itself as a way 
to double the pace of genetic research while allowing its donors to receive fair compensation for the 
valuable information they provide. How DNASimple Works, DNASIMPLE, https://www.dnasimple.
org/about [https://perma.cc/S268-P6LF]. The company’s founder, twenty-eight-year-old Olivier Noel, 
was recognized by Forbes Magazine as a 2017 member of its “30 Under 30 in Science” distinction. 




 6 Stephanie M. Lee, These Startups Will Pay You for Your DNA, BUZZFEED (Dec. 15, 2016), 
https://www.buzzfeed.com/stephaniemlee/these-startups-will-pay-you-for-your-dna?utm_term=.wb
KX0kWwq#.bgrWv9dRl [https://perma.cc/L2GS-HM9Q]. Genos Research is another prominent 
startup that offers individuals monetary compensation for donating their biological material. Id. Cus-
tomers send in a saliva sample of their DNA, and for $499, the San Francisco-based startup will per-
form a genetic sequencing of the sample. Id. Researchers will then use the Genos Research platform to 
acquire DNA samples for their studies by analyzing the company’s database of genetic profiles. Id. If 
the researcher wants to use a participant’s sample, the participant will be paid between $50 and $200 
depending on the study. Id. Presently, the company is focusing its research interests on lymphoma, 
breast and skin cancer, neurological and psychiatric disorders, and a rare type of neurodegenerative 
disorder known as Prion disease. Id. The company has secured a number of high profile advisors such 
as esteemed geneticists George Church and Dietrich Stephan, a Nobel Prize winning economist, and 
other technology executives. Id. Genos Research has raised $6 million thus far from NantOmics, a 
biotechnology company founded by renowned physician and billionaire entrepreneur Patrick Soon-
Shiong. Id. The company charges pharmaceutical companies more than academic and nonprofit insti-
tutions for access to its database. Id. In contrast, DNASimple presently charges scientists $155 for 
every match, $50 of which goes to the customer. Id. Biological samples like those collected by 
DNASimple and Genos Research are projected by some estimates to generate $23 billion in revenue 
by 2018. Daley & Cranley, supra note 5. 
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research and treatment just as significant advancements in the field of preci-
sion medicine are being made.7 
Medical care and treatment is poised for significant change and accelera-
tion in the coming years due to advances in genetic and genomic technology.8 
It has been more than ten years since the completion of the Human Genome 
Project, a thirteen-year, three-billion dollar project to sequence the human ge-
nome.9 Remarkably, by 2015, the cost to sequence a human genome had fallen 
to approximately one thousand dollars.10 Genome sequencing costs are now in 
the range of typical sophisticated medical tests allowing clinicians to use ge-
netic technologies to diagnose developmental disorders, cancers, and other 
diseases.11 Additionally, researchers have used these technologies to better un-
derstand the genetic basis of thousands of diseases and conditions and to de-
velop medical therapies, such as drug regimes, to treat these illnesses.12 
                                                                                                                           
 7 Daley & Cranley, supra note 5. Human DNA derived from biological samples is in high de-
mand as the pharmaceutical industry, government agencies, and academic medical centers seek to 
translate genetic discoveries to medical treatments and therapies. Id. For example, in the field of can-
cer genomics, an insufficient quantity of tissue samples is considered a “rate-limiting step” to the 
progress of the field’s research. Hakimian & Korn, supra note 1, at 2500. 
 8 Susan Young Rojahn, A Decade of Advances Since the Human Genome Project, MIT TECH. REV. 
(Apr. 12, 2013), https://www.technologyreview.com/s/513666/a-decade-of-advances-since-the-human-
genome-project/ [https://perma.cc/4QE9-QF2N]. 
 9 Id. 
 10 The Cost of Sequencing a Human Genome, NAT’L HUM. GENOME RES. INST., https://www.
genome.gov/sequencingcosts/ [https://perma.cc/6T9F-E4D9]. The reduction in cost does not appear 
likely to slow. Id. 
 11 Rojahn, supra note 8. Genetic sequencing holds tremendous promise in aiding in the diagnosis 
of disease. See Carl Zimmer, What’s Behind Many Mystery Ailments? Genetic Mutations, Study 
Finds, N.Y. TIMES (Mar. 15, 2018), https://www.nytimes.com/2018/03/15/health/genetic-mutations-
diagnosis.html [https://perma.cc/WD6F-9FG7] (describing the results of a study that analyzed the 
electronic health records and DNA samples of over twenty-one thousand patients). The researchers 
determined that almost 4% of patients carried a Mendelian disease-linked genetic mutation. Id. Fur-
ther, the study posited that as many as 4.5% of cases of seemingly non-genetic diseases, such as infer-
tility or kidney failure, are the result of these mutations. Id. 
 12 Edward D. Esplin et al., Personalized Sequencing and the Future of Medicine: Discovery, 
Diagnosis and Defeat of Disease, 15 PHARMACOGENOMICS 1771, 1771 (2014). Many of these much-
anticipated pharmacogenomic therapies are just beginning to come to market. See, e.g., Jeannie Bau-
mann, AstraZeneca Drug Approved for Targeted Breast Cancer Therapy, BLOOMBERG BNA LIFE 
SCI. L. & INDUSTRY REP. (Jan. 19, 2018) (describing approval of a drug therapy to treat patients with 
metastatic breast cancer who have a BRCA gene mutation). The Food and Drug Administration’s 
(FDA) approval of AstraZeneca’s Lynparza marked the first time the agency approved any drug to 
treat certain patients with metastatic breast cancer patients that carry a BRCA gene mutation. Id. 
Lynparza can be seen as exemplary of a precision medicine approach to tailoring disease prevention 
and treatment. See id. (“This approval demonstrates the current paradigm of developing drugs that 
target the underlying genetic causes of a cancer, often across cancer types.”) In order to be treated 
with Lynparza, patients suffering from metastatic breast cancer undergo a diagnostic blood test to 
detect BRCA mutations. Id. By treating patients with this particular genetic mutation, a more effec-
tive, targeted, and precise therapy can be delivered. Id. This is particularly significant as patients with 
BRCA-related metastatic breast cancer are often younger than other breast cancer patients, and their 
disease is more aggressive and harder to successfully treat. Id. The FDA has also recently approved a 
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Of significant promise is the prospect that genomic technologies can be 
utilized to predict and prevent disease.13 At present, clinicians utilize these 
technologies to treat diseases as they emerge, using invasive methods and pro-
cedures that are often expensive and have a high morbidity.14 Genomic tech-
nology offers a future of medicine where disease can be prevented if patients 
and medical providers are armed with an individual’s personal genomic pro-
file.15 This information can be used to inform surveillance and lifestyle choic-
es, as well as to develop preemptive pharmacogenomic therapies.16 
The promise and transformational value of these genetic technologies is 
dependent on researchers and clinicians having access to large numbers of hu-
man biological samples.17 There has been a marked increase in demand for 
                                                                                                                           
drug, Merck’s Keytruda, for cancer patients whose tumors share a certain genetic profile, regardless of 
the tumor’s location in the body. See Gina Kolata, Cancer Drug Proves to Be Effective Against Multi-
ple Tumors, N.Y. TIMES (June 8, 2017), https://www.nytimes.com/2017/06/08/health/cancer-drug-
keytruda-tumors.html [https://perma.cc/GAQ9-XJTG] (noting that this is the first time the FDA has 
approved such a drug). Treatment with Keytruda represents a departure from the traditional clinical 
approach to cancer therapy. Id. Clinicians typically categorize cancers by their location in the body, 
instead of the underlying genetic mutation causing the cancerous tumors. Id. The drug, and the associ-
ated diagnostic test to identify the particular genetic mutation, has been used for treatment of lung, 
melanoma, and bladder tumors. Id. 
 13 Esplin et al., supra note 12, at 1787. 
 14 Id. The FDA has recently approved the first ever gene therapy available in the United States. Den-
ise Grady, F.D.A. Approves First Gene-Altering Leukemia Treatment, Costing $475,000, N.Y. TIMES 
(Aug. 30, 2017), https://www.nytimes.com/2017/08/30/health/gene-therapy-cancer.html [https://perma.
cc/ZKC6-9YVZ]. Novartis’s Kymria is used for an aggressive and previously resistant to treatment 
type of leukemia. Id. Gene therapies, such as Kymria, entail the removal of a patient’s white blood 
cells or T cells from their bloodstream, which are then shipped to Novartis for genetic engineering, 
and the reintroduction of the manipulated cells back into the patient’s bloodstream—effectively turn-
ing the patient’s cells into a “living drug” that is trained to recognize and attack cancer cells. Id. The 
FDA also recently approved a gene therapy treatment for a rare, genetic form of blindness. Jeannie 
Baumann, Gene Therapy Cost ‘Sparks’ Debate About Pricing Future Therapies, BLOOMBERG BNA 
LIFE SCI. L. & INDUSTRY REP. (Jan. 19, 2018). Spark Therapeutics, Inc.’s (“Spark”) Luxturna essen-
tially cures blindness in those born with a certain rare genetic mutation. Id. More gene therapies are 
likely to be approved in the future as more than five hundred types of gene therapy are currently being 
studied. Grady, supra. Spark, for instance, is currently working on a gene therapy for hemophilia, a 
rare, genetic disorder that causes blood clots. Baumann, supra. Pharmaceutical giant, Pfizer, an-
nounced in 2016 that it plans to become an “industry leader” in gene therapy, initially focusing on 
gene therapies for ALS. Id. 
 15 Esplin et al., supra note 12, at 1787; see Kate Crawford & Jason Schultz, Big Data and Due 
Process: Toward a Framework to Redress Predictive Harms, 55 B.C. L. REV. 93, 102 (2014) (describ-
ing how technological advancement and more sophisticated health data can improve diagnostic pre-
dictions and treatment suggestions). 
 16 Esplin et al., supra note 12, at 1787. Surveillance, in this context, refers to the ongoing and 
systematic collection and analysis of a person’s health data with the purpose of using that information 
to prevent or control a disease. Medical Definition of Disease Surveillance, MEDICINENET.COM, 
https://www.medicinenet.com/script/main/art.asp?articlekey=26702 [https://perma.cc/ZF9N-QMWF?
type=image]. 
 17 Kayte Spector-Bagdady, The Privacy Debate Over Research with Your Blood and Tissue, 
CONVERSATION (Jan. 25, 2017), https://theconversation.com/the-privacy-debate-over-research-with-
your-blood-and-tissue-71523 [https://perma.cc/U7D3-MCVT]. Personalized medicine requires con-
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human biological material in recent decades, with no reason to suspect the de-
mand will soften in the foreseeable future.18 Consequently, restrictions or addi-
tional barriers on access to the necessary biosamples risk the continued pro-
gress and development of this promising field.19 
Part I of this Note outlines the legal framework in which any asserted bio-
rights operate.20 Part I focuses specifically on the judicial decisions and regula-
tions that guide the biomedical research enterprise in the United States.21 Part 
II addresses the updated regulations regarding biomedical research set to go 
                                                                                                                           
ducting large-scale comparisons of data from thousands of biosamples to identify relationships between 
genetic variation, medical outcomes, and health behavior. Id. In 2015, the Obama administration an-
nounced a $215 million research initiative to collect biosamples from more than a million volunteers who 
would provide biosamples and associated health data. FACT SHEET: President Obama’s Precision Med-
icine Initiative, WHITE HOUSE OFF. PRESS SECRETARY (Jan. 30, 2015), https://obamawhitehouse.
archives.gov/the-press-office/2015/01/30/fact-sheet-president-obama-s-precision-medicine-initiative 
[https://perma.cc/68YR-T64Y]. The Precision Medicine Initiative “[t]hrough collaborative public and 
private efforts . . . will leverage advances in genomics, emerging methods for managing and analyzing 
large data sets while protecting privacy, and health information technology to accelerate biomedical 
discoveries.” Id. Biologically valuable human samples are typically stored in biobanks throughout the 
country to which researchers can obtain access. Daley & Cranley, supra note 5. For example, in Bos-
ton, Partners Healthcare, a $12 billion healthcare system, is seeking to build a biobank with samples from 
over one hundred thousand volunteers for use by the system’s six thousand researchers. Id.; Partners 
HealthCare Reports 2016 Financial Results, PARTNERS HEALTHCARE, http://www.partners.org/
Newsroom/Press-Releases/Financial-Statement-Q42016.aspx [https://perma.cc/NX2Q-4FAH]. The need 
for large numbers of genetically profiled samples is also a concern for developers of genetic sequenc-
ing tests and diagnostic tools. Jeannie Baumann, FDA Posed to Finalize Advanced Genetic Diagnos-
tics Guidance, BLOOMBERG BNA LIFE SCI. L. & INDUSTRY REP. (Jan. 19, 2018). Traditional diagnos-
tic tests detect only a single or a limited number of substances to diagnose a condition; however, next 
generation sequencing technologies identify approximately three million genetic variants an individual 
may possess. Id. The current FDA approval and validation process for these tests, which would review 
each of the three million data points, is impractical. Id. Therefore, the FDA is expected to issue guid-
ance that modernizes the way it approves and validates genetic sequencing tests and diagnostic tools. 
Id. One such guidance would permit developers to rely on certain approved databases to support the 
clinical effectiveness and interpretation of their tests—essentially “crowdsourcing” the supporting 
evidence from a large number of genetically and clinically profiled samples. Id. 
 18 See Hakimian & Korn, supra note 1 (describing the increased demand for biosamples); Spec-
tor-Bagdady, supra note 17 (describing the ambitious goals of precision medicine and the need for 
large numbers of biosamples). 
 19 Daley & Cranley, supra note 5. Leading professional organizations, such as the Association of 
American Universities and the National Academies of Science, Engineering, and Medicine, oppose 
changes to the current collection system out of concern that restrictions on access and high costs would 
stifle medical advances. Id. The emergence of this issue has prompted commentary and attention 
throughout the medical, scientific, and bioethics communities. See Akanksha Jayanthi, In ‘Biorights’ 
Movement, Patients Seek Compensation for Providing Genetic Samples, BECKER HOSP. REV. (Oct. 
11, 2016), http://www.beckershospitalreview.com/healthcare-information-technology/in-biorights-
movement-patients-seek-compensation-for-providing-genetic-samples.html [https://perma.cc/Q45D-
U258] (demonstrating that the issue has catalyzed debate among bioethicists, as well as the healthcare 
and scientific research communities); ‘BioRights’ Rise: Donors Demand Control of Their Samples, BIO-
ETHICS RES. LIBR., GEO. LIBR. (Oct. 10, 2016), https://bioethics.georgetown.edu/2016/10/biorights-rise-
donors-demand-control-of-their-samples [https://perma.cc/YS66-Q5D8] (same). 
 20 See infra notes 25–90 and accompanying text. 
 21 See infra notes 25–90 and accompanying text. 
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into effect in 2018.22 Part III provides an analysis of the updated regulations 
and argues that the regulations do not go far enough to sufficiently prevent the 
harmful consequences of the positions advanced by the biorights movement.23 
Specifically, regulations need to be enacted that explicitly prevent individuals 
from selling their biological material for research purposes.24 
I. THE LEGAL BASIS FOR ASSERTING ONE’S BIORIGHTS 
The emergence of the biorights movement is at its core an expression of 
personal autonomy.25 In a healthcare context, autonomy is particularly im-
portant.26 A respect for autonomy means allowing patients to make informed 
decisions about their medical treatment and care.27 Treating people as autono-
mous agents with rights of self-determination also includes their ability to par-
ticipate in medical research and to “donate” their biological material for re-
search purposes.28 The term donation implies some form of a property or own-
ership right in the biological material.29 The law, however, is unclear in regard 
to the ownership rights of human biological materials.30 
This Part outlines the legal framework guiding any asserted rights to 
one’s biological material.31 Section A discusses the judicial decisions that 
shape the outer boundaries of ownership or property rights to one’s biological 
material as they relate to participation in medical or scientific research.32 Sec-
tion B explores the current statutory and regulatory framework that governs the 
manner in which human subject research is conducted.33 
A. An Individual’s Right to Their Biological Material Extends Only So Far 
In the absence of any abundant clarity, “researchers and institutions have 
assumed they retain the right to collect, study, store, transfer, or dispose of tis-
                                                                                                                           
 22 See infra notes 91–137 and accompanying text. 
 23 See infra notes 138–219 and accompanying text. 
 24 See infra notes 138–219 and accompanying text. 
 25 See Kristin E. Schleiter, Donors Retain No Rights to Donated Tissue, 11 AMA J. ETHICS 621, 
621 (2009) (describing autonomy as the quality or state of self-governing). 
 26 Id. 
 27 Id. 
 28 Id. 
 29 Id. To “donate” means to give (property or money) without receiving consideration for the 
transfer. Donate, BLACK’S LAW DICTIONARY (10th ed. 2014). 
 30 Schleiter, supra note 25, at 621. 
 31 See infra notes 34–90 and accompanying text. 
 32 See infra notes 34–52 and accompanying text. 
 33 See infra notes 53–90 and accompanying text. 
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sue specimens and the associated patient data.”34 Such assumptions have been 
challenged in three noteworthy cases.35 
In what remains the seminal case on the issue, in 1990, in Moore v. Re-
gents of University of California, the Supreme Court of California held that 
individuals do not retain an ownership interest in their cells after the cells are 
removed from their bodies.36 Plaintiff John Moore brought suit against his 
physician and University of California, Los Angeles Medical Center after they 
failed to disclose to him that his spleen tissue and other biological material 
collected, in what Moore assumed was the course of standard clinical care, 
were being used for commercially lucrative research purposes.37 The court ul-
timately found that a cell line derived from the cells of Moore’s surgically ex-
cised spleen was a product of invention and, therefore, not the property of the 
donor.38 Even if the cells initially belonged to Moore, those cells were legally 
and factually distinct from the resulting research product.39 Although techni-
cally only binding in California, the decision was hugely influential in shaping 
                                                                                                                           
 34 Schleiter, supra note 25, at 621. 
 35 See Wash. Univ. v. Catalona, 490 F.3d 667, 676–77 (8th Cir. 2007) (holding that individuals 
who provide biological samples for research do so as irrevocable inter vivos gifts retaining no proper-
ty rights to request the return or transfer of the samples to another party); Moore v. Regents of Univ. 
of Cal., 793 P.2d 479, 493–95 (Cal. 1990) (holding that individuals do not retain an ownership interest 
in their cells after the cells are removed from their bodies); Greenberg v. Miami Children’s Hosp. 
Research Inst., Inc., 264 F. Supp. 2d 1064, 1076 (S.D. Fla. 2003) (holding that voluntarily donating 
biosamples is done absent a contemporaneous expectation of return even though a commercial benefit 
may accrue). The invention at issue in Moore was a cell line, a common but also valuable biological 
research tool. Cell Line, BIOLOGY ONLINE, https://www.biology-online.org/dictionary/Cell_line 
[https://perma.cc/EW5V-FZKR]. Specifically, a cell line is a cell culture, or a cultivation of cells 
grown outside their natural environment in a laboratory, that is immortalized and will proliferate in-
definitely given the appropriate laboratory conditions. Id.; Cell Culture, BIOLOGY ONLINE, https://
www.biology-online.org/dictionary/Cell_culture [https://perma.cc/K5PQ-SAE9]. See generally Jean-
Pierre Gillet, The Clinical Relevance of Cancer Cell Lines, 105 J. NAT’L CANCER INST. 452 (2013) 
(discussing the value but also limitations of using cell lines in cancer research). 
 36 793 P.2d at 493–95. In Moore, the plaintiff, John Moore, sought treatment from the University 
of California, Los Angeles Medical Center (“UCLA”) for a rare form of leukemia. Id. at 481. Moore’s 
physician removed his spleen for therapeutic purposes but used the spleen tissue for research purpos-
es. Id. He did not disclose such a fact to Moore. Id. Moore continued to return to UCLA for several 
years after the procedure under the guise of medical necessity, when in fact the research team needed 
to collect additional samples. Id. The researchers were eventually able to develop and patent a cell line 
from Moore’s samples that was worth approximately three billion dollars. Id. at 482. Moore sought to 
recover a share of the proceeds of the patented cell line bringing claims of conversion and breach of 
physician disclosure obligations. Id. at 482–83. Although the court rejected Moore’s conversion 
claim, it recognized a physician’s duty to disclose economic or research interests to patients when 
seeking consent for a medical procedure. Id. at 493–95. 
 37 Id. at 481–82. 
 38 Id. at 492–93. 
 39 Id. In refusing to impose conversion liability, the court placed significant emphasis on the poli-
cy considerations of not wanting to impede medical research and the derivative social benefits. Id. 
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jurisprudence in this area of law and was the only decision on the issue of 
ownership of biological samples for more than a decade.40 
Similarly, in 2003, in Greenberg v. Miami Children’s Hospital Research 
Institute, Inc., the U.S. District Court for the Southern District of Florida held 
that individuals have no property rights in their body tissue and genetic materi-
al donated for research.41 Unlike in Moore, however, the biological material in 
Greenberg was donated voluntarily and knowingly for research and not ob-
tained during the course of clinical care.42 In Greenberg, the plaintiff ap-
proached a physician-scientist to help identify the genes associated with a rare 
and fatal genetic disease common in the plaintiff’s Ashkenazi Jewish commu-
nity.43 The plaintiff provided researchers with access to biological samples, 
financial support, and helped recruit other Ashkenazi Jewish individuals to 
participate in the research project.44 The court ultimately concluded that the 
materials at issue were voluntarily donated without a contemporaneous expec-
tation of return even though a commercial benefit accrued.45 
Much of the Greenberg court’s reasoning was echoed by the U.S. Court 
of Appeals for the Eighth Circuit, in 2007, in Washington University v. Catalo-
                                                                                                                           
 40 See Hakimian & Korn, supra note 1, at 2502 (describing how no other state or federal court 
ruled on the ownership of tissue samples in research for more than a decade following Moore, which 
was noteworthy given the burgeoning biotechnology industry of the time); Osagie K. Obasogie, Your 
Body, Their Property, BOS. REV. (Sept. 30, 2013), http://bostonreview.net/us/obasogie-gene-patent-
myriad-moore [https://perma.cc/9SP6-HV85] (“[Moore] enshrined a principle in property law that . . . 
patients have virtually no property interest in most of the non-reproductive cells or tissues taken from 
them, even when these materials turn out to be profitable to researchers and institutions. This conclu-
sion by the California Supreme Court has been followed by almost every jurisdiction.”). The Supreme 
Court also denied a Petition for Writ of Certiorari. Moore, 793 P.2d 479, cert. denied, 499 U.S. 936 
(1991). 
 41 264 F. Supp. 2d at 1074–75. The plaintiff, Daniel Greenberg, had initially approached Reuben 
Matalon, MD, PhD, to request his assistance in discovering the genes associated with Canavan dis-
ease, a rare and fatal genetic disease frequently occurring in the Ashkenazi Jewish population. Id. at 
1068. Greenberg and others supplied Matalon with blood, urine, and tissue samples to help in the 
development of a prenatal test that would screen for the disease. Id. With the support of Miami Chil-
dren’s Hospital Research Institute (“MCH”), Matalon was able to isolate and clone the gene associat-
ed with Canavan disease. Id. MCH obtained a patent on the gene and related applications generating 
annual royalties of approximately $375,000. Id. Greenberg filed suit claiming that the defendants had 
a duty to disclose any information that might influence a prospective subject’s decision to participate 
in the research, including the desire to seek a patent and commercial benefit from the research. Id. The 
commercial benefit derived in this case from a patented gene would no longer be realized since the 
U.S. Supreme Court decision to strike down the validity of gene patents. Ass’n for Med. Pathologists 
v. Myriad Genetics, 569 U.S. 576, 580 (2013). In Myriad Genetics, the Court held that naturally-
occurring human genes are not patentable. Id. A naturally-occurring DNA segment is a product of 
nature and is not patent-eligible merely because it has been isolated. Id. 
 42 Greenberg, 264 F.Supp.2d at 1067–68. 
 43 Id. 
 44 Id. 
 45 Id. at 1076. The court looked to the reasoning in Moore in declining to extend conversion lia-
bility to body tissue and genetic material donated for research, as well as Florida state court decisions 
that limit property rights attached to body tissue. Id. at 1075–76. 
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na.46 There, the court held that individuals who provided biological samples 
for research did so as inter vivos gifts and retained no property rights that 
would allow them to request the return of the samples or the transfer to a third 
party.47 The court determined that the research participants voluntarily donated 
the samples for research, and once the donative transfer was completed, the 
gift was irrevocable.48 
The aforementioned cases demonstrate that while individuals have the 
right to donate bodily tissues for research purposes, the right to own and retain 
control of donated tissues is extinguished once those tissues leave the body.49 
Such a loss encompasses any claim of commercial benefit acquired through the 
development of products derived from the tissue.50 Courts have consistently 
expressed concern that if patients were able to retain ownership rights over 
their biosamples, research could not be performed efficiently or effectively.51 
Patients remain free, however, to enter into legal contracts prior to the removal 
of their biological material that allow them to retain certain property rights in 
that material.52 
                                                                                                                           
 46 Catalona, 490 F.3d at 676–77. In Catalona, a physician-scientist’s patients signed consent 
forms contributing their biological samples to a biorepository at the researcher’s institution of Wash-
ington University. Id. at 670–71. When the researcher requested the transfer of the samples to a pri-
vate research laboratory and later to another academic medical center, Washington University refused 
to authorize the transfer of the samples despite the patients requesting as such. Id. The patients sued 
claiming ownership rights to their tissue, which included the ability to transfer the tissues to another 
institution. Id. at 672–73. An inter vivos gift is a gift of personal property made during the donor’s 
lifetime and delivered to the donee with the intention of irrevocably surrendering control over the 
property. Inter vivos gift, BLACK’S LAW DICTIONARY (10th ed. 2014). 
 47 Catalona, 490 F.3d. at 676–77. 
 48 Id. 
 49 See Carlo Petrini, Ethical and Legal Considerations Regarding the Ownership and Commercial 
Use of Human Biological Materials and Their Derivatives, 2012 J. BLOOD MED. 87, 92 (describing 
how the aforementioned cases indicate that case law is generally oriented towards recognizing certain 
assertions regarding ownership). 
 50 Id. 
 51 See Moore, 793 P.2d at 492–93 (placing significant emphasis on encouraging the burgeoning 
biotechnology industry at the time and the desire to not impede societally valuable medical and scien-
tific research); Greenberg, 264 F. Supp. 2d at 1076 (warning that imposing conversion liability on 
research institution for use of donated biosamples would cripple medial research); see also Sarah Dry 
et al., Stuck Between a Scalpel and a Rock, or Molecular Pathology and Legal-Ethical Issues in Use 
of Tissues for Clinical Care and Research, 137 AM. J. CLINICAL PATHOLOGY 346, 350 (2012) (noting 
that “courts consistently have rejected the idea that patients are the owners of their removed bi-
osamples that are used for research purposes” as ownership could further frustrate the research pro-
cess). 
 52 Dry et al., supra note 51, at 350. An influential article on the tissue-industrial complex ap-
peared in a 2006 issue of The New York Times Magazine. Rebecca Skloot, Taking the Least of You, 
N.Y. TIMES MAG. (Apr. 16, 2006), http://www.nytimes.com/2006/04/16/magazine/taking-the-least-
of-you.html [https://perma.cc/DJ9J-THSQ]. The article describes how in the 1970s, Ted Slavin, upon 
learning that his blood contained highly valuable Hepatitis B antibodies, sold his blood to laboratories 
and companies in what was an unusual arrangement at the time. Id. Hepatitis B is a liver infection 
caused by the Hepatitis B virus that is transmitted when blood, semen, or another body fluid from a 
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B. Confusion Abounds in Statutory and Regulatory Framework 
Human subject research in the United States that is conducted or support-
ed by federal agencies is governed by federal regulations.53 Although techni-
cally only research that is federally funded or conducted by federal agencies 
must adhere to the applicable federal regulations, in practice, many institutions 
require all research proposals to adhere to federal regulation standards.54 Addi-
tionally, state or local laws may impose additional forms of research subject 
protection.55 
Federal policies on human research are specified in the Code of Federal 
Regulations in what has been termed the Common Rule.56 The Department of 
Health and Human Services’ (“HHS”) Office for Human Research Protections 
is responsible for the interpretation and oversight of the Common Rule.57 The 
Food and Drug Administration (FDA) provides an additional regulatory 
framework for some types of human subject research.58 Subsection 1 of this 
Section outlines the regulatory framework governing issues of consent for hu-
man subjects research.59 Subsection 2 of this Section describes the regulatory 
guidelines that address issues of ownership of human biological material.60 
                                                                                                                           
person infected with the Hepatitis B virus enters the body of someone who is not infected. Hepatitis B 
Information, CTRS. FOR DISEASE CONTROL & PREVENTION, https://www.cdc.gov/hepatitis/hbv/ 
[https://perma.cc/P99T-YTAT]. This can happen through sexual contact, sharing needles, syringes, or 
other drug-injection equipment, or from mother to baby at birth. Id. A test for Hepatitis B, a multi-
billion-dollar market, required a significant supply of the antibodies in Slavin’s blood. Skloot, supra. 
Slavin’s blood was also used to help uncover the link between Hepatitis B and liver cancer and the 
first Hepatitis B vaccine. Id. Slavin later created a company that recruited other people with valuable 
blood. Id. The difference between Slavin and the plaintiff in Moore was not that Slavin owned his 
tissues and the plaintiff in Moore did not. Id. It was that Slavin was told his tissues were valuable to 
researchers and was able to control the use of them before they left his body. Id. 
 53 See 45 C.F.R. § 46.101 (2016) (outlining which types of human subjects research are subject to 
federal regulations). 
 54 See R. HAKIMIAN ET AL., NAT’L CANCER INST. CANCER DIAGNOSIS PROGRAM, 50-STATE 
SURVEY OF LAWS REGULATING THE COLLECTION, STORAGE, AND USE OF HUMAN TISSUE SPECI-
MENS AND ASSOCIATED DATA FOR RESEARCH 90 n.3 (2004), https://ntrl.ntis.gov/NTRL/dashboard/
searchResults/titleDetail/PB2006100582.xhtml [https://perma.cc/N2FN-4T4J] (“While the Common 
Rule only applies to human subjects research that is federally funded or conducted, many research 
institutions have agreed to subject all of their research activities to its requirements.”). 
 55 Dry et al., supra note 51, at 351. 
 56 Federal Policy for the Protection of Human Subjects (‘Common Rule’), U.S. DEP’T HEALTH & 
HUM. SERVS., https://www.hhs.gov/ohrp/regulations-and-policy/regulations/common-rule/index.html 
[https://perma.cc/U4B2-3RBD] (describing how the Federal Policy for the Protection of Human Sub-
jects or Common Rule was published in 1991 and codified in separate regulations by fifteen federal 
agencies, with the applicable Department of Health and Human Services (“HHS”) regulations located 
in 45 C.F.R. Part 46). 
 57 Hakimian & Korn, supra note 1, at 2501. 
 58 See 21 C.F.R. § 50.1 (2016) (stating that the FDA’s purview extends to clinical investigations 
involving drugs or biological products for human use). 
 59 See infra notes 61–82 and accompanying text. 
 60 See infra notes 83–90 and accompanying text. 
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1. Informed Consent Standards 
Informed consent serves many purposes.61 In a clinical context, it serves 
to permit patients to make informed choices about the appropriate options for 
their care.62 Informed consent is often viewed as a rejection of the notions of 
paternalism often pronounced in medicine.63 In therapeutic research, such as 
participation in a clinical trial, informed consent serves a similar function to 
that in clinical care with the notable exception that the experimental option 
could be ineffective or even harmful, necessitating the need for more thorough 
consent procedures.64 Nontherapeutic research, however, offers no prospect of 
direct benefit to the subject.65 The benefit, if any, may accrue to the individual 
in the future or to others in society.66 
Appropriate consent guidelines vary according to the purpose for which 
human biological material is collected.67 For instance, a biological sample col-
lected in the course of therapeutic treatment, like a biopsy, has different con-
sent considerations than for what is collected as “surgical leftovers.”68 Addi-
tionally, samples collected for one purpose may be subsequently used for oth-
ers.69 Consent practices also need to be tailored to each type of intervention.70 
Consequently, general consent guidelines are infeasible.71 Consent standards 
                                                                                                                           
 61 Jeffrey R. Botkin, Informed Consent for the Collection of Biological Samples in Household 
Surveys, in 12 CELLS AND SURVEYS: SHOULD BIOLOGICAL MEASURES BE INCLUDED IN SOCIAL SCI-
ENCE RESEARCH 276, 277–78 (Caleb E. Finch et al. eds., 2001) (describing how the emergence of 
informed consent parallels the consumer rights movement in society more broadly). 
 62 Id. at 278. 
 63 Id. 
 64 Id. 
 65 Id. at 278–79. 
 66 Id. Some of the most egregious examples of abuse in U.S. biomedical research have involved 
nontherapeutic research projects, some even involving federal agencies, such as the Tuskegee syphilis 
experiments and human radiation experiments. Id. Such incidences are widely considered to have 
driven the development of informed consent requirements and other research participant protections. 
Id. 
 67 Petrini, supra note 49, at 87. 
 68 Id. A biopsy is a procedure to remove a piece of tissue or a sample of cells from your body so that 
they can be analyzed in a laboratory. Biopsy: Types of Biopsy Procedures Used to Diagnose Cancer, 
MAYO CLINIC, http://www.mayoclinic.org/diseases-conditions/cancer/in-depth/biopsy/art-20043922 
[https://perma.cc/AV4M-B7MM]. Surgical leftovers refer to the tissue that is removed from patients 
during an operation as part of their clinical care and that would normally be disposed of as medical waste. 
Material Leftover from an Operation, IMPERIAL C. LONDON, http://www.imperial.ac.uk/imperial-
college-healthcare-tissue-bank/collection-of-tissue/material-leftover-from-an-operation/ [https://perma.
cc/87VZ-4TSR]. 
 69 Petrini, supra note 49, at 87. 
 70 Id. 
 71 Id.; see Christine Grady, The Changing Face of Informed Consent, 376 NEW ENG. J. MED. 856, 
857 (2017) (“Even those who favor requiring consent for biospecimen research disagree about wheth-
er consent should be broad enough or a wide range of future possible research or specific for each use, 
one-time or ongoing, and opt-in or opt-out.”). See generally Amy L. McGuire & Laura M. Beskow, 
Informed Consent in Genomics and Genetic Research, in 11 ANN. REV. OF GENOMICS & HUM. GE-
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and requirements for the collection of human biological material are dictated 
by the context in which the samples are obtained, as well as the purpose for 
which the samples are collected.72 
Responsibility for compliance with federal regulations, including informed 
consent requirements, is tasked to institutional review boards (“IRBs”).73 IRBs 
are internal institutional committees composed of research scientists, regulato-
ry compliance staff, legal experts, and members of the lay public.74 These 
boards interpret federal guidelines and apply them to submitted research pro-
posals from their institutions to ensure regulatory compliance.75 
Informed consent and IRB review are required when researchers obtain 
from living individuals “identifiable private information” or “data through in-
teraction or intervention with the individual.”76 Additionally, federal regula-
tions dictate a variety of elements that must be included in obtaining informed 
consent.77 Certain types of human subject research, however, can be exempted 
from the informed consent requirement.78 
Federal regulations have allowed research use of patient biosamples ob-
tained without informed consent as long as the patient’s identity is unknown; 
the sample must be anonymized.79 Further, biosamples not obtained specifical-
ly for research use through an intervention or interaction with a living person, 
                                                                                                                           
NETICS (2010) (describing how traditional standards of consent are incompatible with modern re-
search techniques and methodologies as the scope of future research with collected biosamples cannot 
be foreseen at the time of collection). 
 72 Petrini, supra note 49, at 87. 
 73 See 45 C.F.R. § 46.109 (a) (2016) (stating that “[a]n IRB [Institutional Review Board] shall 
review and have authority to approve, require modifications in (to secure approval), or disapprove all 
research activities covered by this policy”). 
 74 See id. § 46.107 (detailing the requirements for a valid IRB including membership criteria). 
 75 Id. 
 76 Hakimian & Korn, supra note 1, at 2501; see 45 C.F.R. § 46.102(f) (defining “human subject” 
research subject to federal regulation). 
 77 See 45 C.F.R. § 46.116 (detailing the informed consent requirements). In the rulemaking pro-
cess culminating in the enactment of the original version of the Common Rule in 1991, the applicable 
agencies did address comments that “research that could involve sensitive data could place the sub-
jects at risk, even if information is not recorded in such a manner that human subjects be identified 
and should not be exempt from provisions of the Policy.” Federal Policy for the Protection of Human 
Subjects; Notices and Rules, 56 Fed. Reg. 28,002, 28,007 (June 18, 1991) (codified at 45 C.F.R. pt. 
46). One comment noted that “one IRB reviews this type of research even if an exemption is permitted 
by the regulations.” Id. The agencies responded that “at a later date” they may consider incorporation 
of stricter provisions, but “such considerations should not delay publication of basic protections for all 
human subjects.” Id. 
 78 See 45 C.F.R. § 46.116. (describing how the IRB may approve a consent procedure which does 
not include, or which alters, some or all of the elements of informed consent set forth above,or waive 
the requirement to obtain informed consent). 
 79 Id. § 46.102(f); Dry et al., supra note 51, at 352; Coded Private Information or Specimens Use in 
Research, Guidance, U.S. DEP’T HEALTH & HUM. SERVS. (Oct. 16, 2008), https://www.hhs.gov/ohrp/
regulations-and-policy/guidance/research-involving-coded-private-information/index.html [https://perma.
cc/FW9N-HP4D]. 
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such as a diagnostic biopsy, are exempted from informed consent require-
ments.80 From a bioethical perspective, samples obtained in the course of clinical 
care seem distinct from those obtained from formal research studies.81 Some 
bioethicists consider the former type of tissue to be “abandoned” by patients.82 
2. Ownership of Human Biological Material 
Regulatory ambiguity persists for issues of ownership of biosamples.83 
Typically, when informed consent is obtained to study a sample, consent forms 
do not address the issue of tissue ownership, either by the individual who is the 
source of the specimen, the investigator, or the institution.84 When tissues are 
collected without informed consent as part of clinical care, issues of ownership 
are also not considered.85 Researchers are presently unable to use informed 
consent language that either confers or curtails individual ownership rights in 
tissue samples.86 The FDA prohibits the use of the term “donation” in consent 
forms because it implies a waiver of ownership.87 Additionally, no state laws 
establish individual ownership rights in tissue samples.88 At present, research-
ers are afforded a fair degree of latitude in using biosamples for a variety of 
research purposes, despite a relatively unclear legal and regulatory frame-
                                                                                                                           
 80 45 C.F.R. § 46.102(f); Coded Private Information or Specimens Use in Research, Guidance, 
supra note 79. 
 81 Dry et al., supra note 51, at 352. Bioethics is concerned “with the ethics and philosophical impli-
cations of certain biological and medical procedures, technologies, and treatments.” Bioethics, DICTION-
ARY.COM, http://www.dictionary.com/browse/bioethics [https://perma.cc/PVC9-CLBE?type=image]. 
 82 Dry et al., supra note 51, at 352. 
 83 Hakimian & Korn, supra note 1, at 2501. 
 84 Id. 
 85 Id. 
 86 See 45 C.F.R. § 46.116 (stating that “[n]o informed consent, whether oral or written, may in-
clude any exculpatory language through which the subject or the representative is made to waive or 
appear to waive any of the subject’s legal rights, or releases or appears to release the investigator, the 
sponsor, the institution or its agents from liability for negligence”). The unsettled legal framework 
regarding ownership rights has likely prompted the lack of clarity by federal regulators. Hakimian & 
Korn, supra note 1, at 2501. In 1987, three years prior to the decision in Moore, the U.S. Office of 
Technology Assessment published a study of the legal, economic, and ethical considerations relating 
to the ownership of human cells and tissues and concluded that there “is great uncertainty about how 
courts will resolve disputes between the human sources of specimens and specimen users.” Id. In 
1996, the HHS’ Office of Human Research Protection (“OHRP) published guidelines that specifically 
addressed the proscription of consent form language that implies some form of waiving one’s legal 
rights. Id. The guidelines state that asking participants to relinquish any property rights was exculpato-
ry despite the fact that no such legal rights have been established. Id. In 2001, the OHRP reiterated its 
stance when it said that participants could also not be asked to relinquish continuing ownership rights 
in their tissue. Id. 
 87 Hakimian & Korn, supra note 1, at 2501. 
 88 Id.; see HAKIMIAN ET AL., supra note 54, at 7–8 (noting that no state statutes have addressed 
the ownership of tissue samples, and the few states that have passed statutes addressing ownership of 
“genetic information” still permit the use and retention of such information when the data is anony-
mous). 
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work.89 Proposed changes to the current system would have done more harm 
than good, but that by no means is to say that the current system would not 
benefit from change and modernization.90 
II. ALTHOUGH THE PROPOSED CHANGES TO THE COMMON RULE ARE A STEP 
IN THE RIGHT DIRECTION, THE EXISTING REGULATORY FRAMEWORK DOES 
NOT PROVIDE ADEQUATE PROTECTION FOR MODERN RESEARCH 
Section A of this Part discusses the benefits of the proposed changes to 
the Common Rule and applauds the regulations for their recognition of the 
way doing research has evolved in the past thirty years.91 Section A also notes, 
however, that the updated regulations remain silent on the issue of ownership, 
and that they fail to address the issue of offering compensation for biosamples 
contributed for research purposes.92 In the absence of any update to the Com-
mon Rule that specifically addresses the sale of biosamples for research pur-
poses, this Part explores the legal, regulatory, and economic framework regard-
ing the non-proscribed sale of certain biological material.93 In regard to the 
sale of human biological material, the National Organ Transplant Act (the 
“Transplant Act”) is explicit that the trafficking of vital organs for profit is pro-
scribed.94 The law is less explicit in regard to the sale of other biological mate-
rial.95 Section B addresses the sale of bone marrow.96 Section C provides a 
similar analysis for blood and plasma donation.97 
A. Bringing the Common Rule into the Twenty-First Century 
In September 2015, HHS and fifteen other federal agencies published a 
Notice of Proposed Rulemaking (“NPRM”) in regard to updating the Common 
Rule.98 The Common Rule had been in effect since 1991 and was drafted at a 
                                                                                                                           
 89 See supra notes 25–88 and accompanying text. 
 90 See infra notes 91–129 and accompanying text. 
 91 See infra notes 98–113 and accompanying text. 
 92 See Final Rule, infra note 98 (leaving both of these issues unaddressed). 
 93 See infra notes 98–137 and accompanying text. 
 94 42 U.S.C. § 274e(c)(1) (2012). The statute states: “It shall be unlawful for any person to know-
ingly acquire, receive, or otherwise transfer any human organ for valuable consideration for use in 
human transplantation if the transfer affects interstate commerce. The preceding sentence does not 
apply with respect to human organ paired donation.” Id. The statute defines a “human organ” as “hu-
man (including fetal) kidney, liver, heart, lung, pancreas, bone marrow, cornea, eye, bone, and skin or 
any subpart thereof” as well as any other human organ specified by the HHS Secretary. Id. 
 95 See infra notes 114–137 and accompanying text. 
 96 See infra notes 114–121 and accompanying text. 
 97 See infra notes 122–137 and accompanying text. 
 98 Final Rule Enhances Protections for Research Participants, Modernizes Oversight System, U.S. 
DEP’T HEALTH & HUM. SERVS., https://www.hhs.gov/about/news/2017/01/18/final-rule-enhances-
protections-research-participants-modernizes-oversight-system.html [https://perma.cc/Z259-4BDB] 
[hereinafter Final Rule]. 
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time when research was conducted predominantly at a single site by universi-
ties and academic medical centers.99 The NPRM drew more than 2100 com-
ments.100 In January 2017, the updated regulations, which will largely go into 
effect in 2018, were released in what has been generally seen as a win for the 
research community.101 A widely criticized provision that sought to require 
consent for use of a study participant’s de-identified biosamples was removed 
from the final rule.102 The final rule maintains the current practice with respect 
to de-identified biosamples.103 The final rule also contains a number of chang-
es to the current regulatory framework relating to other aspects of informed 
consent.104 Such changes are largely intended to reduce the administrative bur-
                                                                                                                           
 99 Id. According to the HHS Press Release announcing the final rule: “The new rule strengthens 
protections for people who volunteer to participate in research, while ensuring that the oversight sys-
tem does not add inappropriate administrative burdens, particularly to low-risk research. It also allows 
more flexibility in keeping with today’s dynamic research environment.” Id. The updated regulations 
sought to account for the fact that human subjects research has dramatically increased in scale and 
diversity. Id. Additionally, much of the data gathered is digital and easily transferrable between re-
search groups and institutions throughout the world. Id. 
 100 Id. Most of the comments focused on whether informed consent should be required before 
using an individual’s de-identified biosample. Spector-Bagdady, supra note 17. Approximately 80% 
of commenters opposed the proposal. Id. 
 101 See Federal Policy for the Protection of Human Subjects: Delay of the Revisions to the Feder-
al Policy for the Protection of Human Subjects, 83 Fed. Reg. 2885, 2885 (Jan. 22, 2018) (delaying the 
effective date of the final rule six months from January 19, 2018, to July 19, 2018); Dianne J. Bour-
que, Newly Updated Common Rule Is Here—And on Collision Course with 21st Century Cures Act, 
NAT’L L. REV. (Jan. 26, 2017), http://www.natlawreview.com/article/newly-updated-common-rule-
here-and-collision-course-21st-century-cures-act [https://perma.cc/TA7J-QC2C] (describing the chal-
lenges associated with harmonizing the Common Rule with the 21st Century Cures Act); Scott 
Jaschik, U.S. Issues Final Version of ‘Common Rule’ on Research Involving Humans, INSIDE HIGHER 
EDUC. (Jan. 19, 2017), https://www.insidehighered.com/news/2017/01/19/us-issues-final-version-
common-rule-research-involving-humans [https://perma.cc/4L5E-S87A] (describing the final rule as a 
win for research universities). The Association of American Universities and the Association of Pub-
lic Land-Grant Universities were largely supportive of the final rule. Jaschik, supra. Shortly after the 
announcement of the final rule, the organizations issued a joint statement noting that requiring univer-
sities and scientists to obtain consent for potentially billions of de-identifiable biosamples would be 
administratively burdensome and costly, as well as impede vital research initiatives. Id. Support for 
the enhanced consent procedures for de-identified biosamples largely came from the professional 
anthropological community. Id. The American Anthropological Association viewed the consent re-
quirement as a way to protect patients and increase transparency within the research community. Id. 
They advanced a position that additional administrative burdens would not make conducting research 
impossible, just more protective of patients and participants. Id. 
 102 Final Rule, supra note 98. 
 103 Id. 
 104 Id. In regards to the text requisite in consent forms, for instance, the final rule requires consent 
forms to include at the beginning of the document a concise explanation of the key information im-
portant to a participant such as the research’s purpose and its risks and benefits. Id. Jerry Menikoff, 
MD, who directed the regulatory overhaul stated: “Over the years, many have argued that consent 
forms have become these incredibly lengthy and complex documents that are designed to protect 
institutions from lawsuits, rather than providing research subjects with information they need in order 
to make an informed choice about whether to participate in a research study.” Id. 
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dens for researchers and research participants.105 The final rule also helps to 
harmonize discrepancies between HHS and FDA regulations, conforming with 
the FDA’s policy that explicitly permits the use of leftover de-identified blood 
and tissue samples for secondary research.106 
Although safety and privacy for human research participants remains of 
paramount importance, the final rule recognizes that these needs must be bal-
anced with enabling scientific progress and technological advances.107 Addi-
tionally, there was concern that the proposal would result in fewer available 
biosamples as smaller institutions would not be able to implement administra-
tively expensive consent processes.108 This could impact the diversity of sam-
ples collected, as community clinics and local hospitals that serve diverse pop-
ulations would be least well-positioned to implement such consent process-
es.109 Large academic medical centers that have the resources to implement 
such processes typically serve a less diverse community.110 
The updated regulations, however, remain silent on the issue of owner-
ship, and they fail to address the issue of offering compensation for biosamples 
contributed for research purposes.111 Other areas of the legal and regulatory 
system are also silent on this issue.112 The federal government’s approach to 
the most analogous situation to selling biosamples for research purposes, sell-
ing blood or bone marrow, could be considered to encourage the sale of bi-
osamples and, therefore, offers no recourse that could prevent such a prac-
tice.113 
                                                                                                                           
 105 Id. Additional changes include requiring a single IRB to oversee multi-institutional research 
studies and creating new exempt categories of research based on the level of risk they pose to partici-
pants. Id. Some ongoing research studies will not be subject to continuing IRB reviews if the reviews 
are considered to do little to protect subjects. Id. 
 106 Bourque, supra note 101. The 21st Century Cures Act includes a mandate for HHS and the 
FDA to harmonize differences between the Common Rule and FDA Human Subject Protection regu-
lations by January 2020. Id. The final rule helps further the goal of reducing regulatory duplication 
and delay. Id. 
 107 Spector-Bagdady, supra note 17. 
 108 Id. 
 109 Id. Genetic research already faces significant criticism and concern that it does not represent a 
sufficiently diverse population. Id. African and Hispanic individuals represent only 5% of participants 
involved in studies that seek to identify associations between gene disruption and disease. Id. The lack of 
diversity in research studies is not limited to genetic research. See Carolyn Plunkett et al., Worth the 
Money? Paying to Ensure a Representative Cohort in Precision Medicine Initiative, HEALTH AFF. (July 
30, 2015), http://healthaffairs.org/blog/2015/07/30/worth-the-money-paying-to-ensure-a-representative-
cohort-in-the-precision-medicine-initiative [https://perma.cc/GEN6-9NKL] (noting that between 1993 
and 2013, less than 5% of participants in National Institutes of Health supported studies identified as non-
white and less than 5% of all studies on respiratory diseases reported the inclusion of members of ethnic 
and racial minorities). 
 110 Spector-Bagdady, supra note 17. 
 111 See Final Rule, supra note 98 (leaving both of these issues unaddressed). 
 112 See infra notes 114–137. 
 113 See infra notes 114–137. 
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B. You Can Sell Your Bone Marrow (but Only Because  
Technology Has Made It Easier to Do So) 
In 2012, in Flynn v. Holder, the U.S. Court of Appeals for the Ninth Circuit 
held that language in the Transplant Act proscribing the sale of bone marrow did 
not prohibit offering compensation for bone marrow donations by a non-invasive 
blood-based collection method.114 In finding so, the court made a distinction be-
tween two types of bone marrow.115 The sale of bone marrow that is the soft, 
fatty substance within bone cavities, extracted with a needle, is illegal under the 
Transplant Act.116 Conversely, bone marrow obtained through a blood-based 
extraction method is not proscribed under the Transplant Act and, therefore, is 
acceptable to be exchanged for compensation.117 The court did recognize that 
Congress had a rational basis in preventing human body parts being viewed as 
commodities by prohibiting compensation for the donation of bone marrow.118 
The government also expressed concern—a concern ultimately seen as non-
determinative by the court—about the prospect of exploitative market forces 
should compensation be permitted for bone marrow donation.119 Although the 
market for bone marrow stem cells is still in its early stage, there are centers that 
                                                                                                                           
 114 Flynn v. Holder, 684 F.3d 852, 857 (9th Cir. 2012). The plaintiffs brought an equal protection 
challenge to the ban on compensation for bone marrow transplants. Id. at 856. Plaintiffs included, 
among others, the parents of leukemia and anemia-stricken children who need bone marrow trans-
plants, the parent of a mix raced child, and a California-based nonprofit that sought to offer $3,000 
scholarships, housing allowances, or charitable gifts to predominantly mixed race or minority bone 
marrow donors. Id. at 857. Deep genetic compatibility is critical in blood marrow transplants. Id. All 
donations, except from one’s identical twin, create a graft-versus-host disease. Id. Consequently, the 
more diverse one’s genetic background, the rarer the match. Id. This makes finding donors for mixed 
race individuals incredibly difficult, so the nonprofit plaintiff sought to mitigate this matching prob-
lem by creating financial incentives to donate bone marrow. Id. at 858. The plaintiffs argued that bone 
marrow harvesting was not materially different than blood, sperm, and egg harvesting which was not 
proscribed under the Transplant Act. Id. Advances in bone marrow harvesting had created a method 
no different than donating blood; the process just took hours longer and required that the blood pass 
through a machine that separates out the desired bone marrow stem cells. Id. This process, referred to 
as peripheral blood cell apheresis, was not in existence when the Transplant Act was passed and bone 
marrow donation required an in-patient procedure where a large needle was used to extract marrow 
directly from within a donor’s hipbone. Id. at 856; see supra note 94 (describing the specific prohibi-
tions of the Transplant Act). 
 115 Flynn, 684 F.3d at 857. 
 116 Id. 
 117 Id. 
 118 Id. at 859. 
 119 Id. In drafting the Transplant Act, the court recognized that Congress had valid public policy 
reasons for prohibiting compensation for organ donation. Id. at 860. Congress could have rightly been 
concerned about poorer individuals being exploited by richer individuals into incurring excessive risk, 
pain, or disability. Id. Donees could exact “your money or your life” offers from those in need. Id. 
Compensation for organs might degrade the quality of the organ supply as donors might be inclined to 
lie about their medical histories increasing the risk of serious medical complications. Id. The court 
also recognized that philosophically there is aversion to the removal of one’s flesh for use by another 
and the commodification of one’s bodily tissue. Id. 
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will pay up to eight-hundred dollars for a single donation.120 It remains unclear, 
however, if there is sufficient interest and demand for such arrangements.121 
C. You Can Sell Your Blood and Plasma, but There Might Not Be a Buyer 
There are no laws proscribing the sale and purchase of blood.122 The ap-
plicable FDA regulations only require that blood from paid donors be labeled 
as such.123 In practice, however, most hospitals and medical providers refuse to 
accept blood that is paid for out of concern that doing so creates a riskier pa-
tient population and a higher chance of contaminated and potentially danger-
ous blood.124 There is also a concern that by providing compensation to pro-
spective donors, donors might be more inclined to lie about their health or risk 
behaviors.125 
In contrast, there is a healthy market for blood plasma obtained through 
compensation arrangements.126 There is no labeling requirement indicating a 
paid donor status for plasma.127 Unlike in a simple blood donation, plasma is 
not necessarily transfused into another person; instead, it can be broken down 
into its components for usage in pharmaceutical products.128 Concerns that 
providing payment for blood plasma encourages people to lie about their 
                                                                                                                           
 120 JoNel Aleccia, Hutch Pays Up to $800 for Blood Stem Cell Donations, but Donors Are Hard 
to Find, SEATTLE TIMES (Jan. 1, 2016), http://www.seattletimes.com/seattle-news/health/a-different-
kind-of-blood-donation-hutch-seeks-cells-for-science/ [https://perma.cc/U2PH-C4XY]. 
 121 See id. (noting that finding enough donors can often be a challenge despite the financial incen-
tive). 
 122 See 42 U.S.C. § 274e(c)(1) (2012) (failing to include blood as one of the human organs that 
cannot be sold). 
 123 See 21 C.F.R. § 606.121 (2016) (specifying that container labels must include “paid donor” if 
applicable); Requirements for Blood and Blood Components Intended for Transfusion or for Further 
Manufacturing Use, 80 Fed. Reg. 29848 (May 22, 2015) (codified at 201 C.F.R. pt. 606) (“FDA regu-
lations do not preclude paid donations for blood for transfusion or for further manufacture.”) 
 124 Elizabeth Preston, Why You Get Paid to Donate Plasma but Not Blood, STAT NEWS (Jan. 22, 
2016), https://www.statnews.com/2016/01/22/paid-plasma-not-blood/ [https://perma.cc/KUD7-YXQD1]; 
see Karen Brown, How Medical Advances Have Affected the Blood Bank Industry, WBUR (Feb. 14, 
2017), http://www.wbur.org/commonhealth/2017/02/14/blood-economy [https://perma.cc/VJE7-TMD2] 
(describing the financial strain blood banks are experiencing as hospitals increasingly perform more 
minimally invasive surgeries so as to rely less on blood transfusions and the associated risks of infection). 
 125 Preston, supra note 124. For instance, the concern of deception on the part of donors is particular-
ly relevant to the American Red Cross which was recently fined $10 million by the FDA for a number of 
violations, including the ineffective screening of donors. Lena Groeger, $10 Million Fine on Red Cross 
Highlights Its Troubled History of Blood Services, PROPUBLICA (Feb. 2, 2012), https://www.pro
publica.org/article/10-million-fine-on-red-cross-highlights-its-troubled-history-of-blood-servi [https://
perma.cc/4EX5-SPF6]. 
 126 Preston, supra note 124. During a plasma donation, blood is drawn from the arm and channeled 
through an automated machine that collects plasma from the blood and returns the remaining blood com-
ponents. Plasma Donation, AM. RED CROSS, http://www.redcrossblood.org/donating-blood/types-
donations/plasma [https://perma.cc/VHG6-C7RB]. 
 127 Preston, supra note 124. 
 128 Id. 
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health or risk behaviors are mitigated, as the plasma is subject to stringent 
screening and processing that removes or kills any blood-based viruses.129 
There is a substantially lessened risk of infection being transmitted through the 
plasma.130 
The market for plasma donation in the United States is quite robust with 
plasma obtained from paid donors making up approximately seventy percent 
of plasma collections worldwide.131 The number of donations has also in-
creased substantially in recent years, with more than twenty-three million do-
nations recorded in 2011, up from twelve million in 2006.132 The compensation 
offered for a donation is approximately fifty dollars for the first few donations 
and then sixty dollars per week if two donations are made in that period.133 
In addition to the proposed updates to the Common Rule failing to address 
the issue of exchanging compensation for biosamples, there are no other statuto-
ry or regulatory mechanisms for proscribing such sales.134 In fact, the current 
system for donating blood does not explicitly proscribe providing compensation, 
even if such a practice has not been adopted by the blood bank industry.135 Addi-
tionally, the exchange of plasma or bone marrow is not proscribed by the legisla-
ture or regulatory agencies and is even sanctioned by the judiciary.136 Therefore, 
the current system provides no avenue of recourse to prevent the significant 
problems created by allowing the exchange of compensation for biosamples.137 
III. THE REGULATIONS NEED TO GO FURTHER TO ADDRESS THE CRUCIAL 
ISSUE OF COMPENSATION FOR BIOSAMPLE DONATION 
The recently announced updates to the Common Rule are widely seen as 
a win for the research community.138 The requirement to obtain consent for the 
collection of de-identified biosamples threatened to hinder a valuable resource 
                                                                                                                           
 129 Id. 
 130 Id. 
 131 Darryl Lorenzo Wellington, The Twisted Business of Donating Plasma, THE ATLANTIC (May 28, 
2014), http://www.theatlantic.com/health/archive/2014/05/blood-money-the-twisted-business-of-donating-
plasma/362012/ [https://perma.cc/3ANL-P886]. Since 2008, the plasma therapeutics market has grown 
from $4 to $11 billion. Id. 
 132 Id. 
 133 Id. 
 134 See supra notes 98–133 and accompanying text. 
 135 See supra notes 122–125 and accompanying text. 
 136 See supra notes 114–133 and accompanying text. 
 137 See supra notes 98–133 and accompanying text. 
 138 Jocelyn Kaiser, Update: U.S. Abandons Controversial Consent Proposal on Using Human Re-
search Samples, SCIENCE (Jan. 18, 2017), http://www.sciencemag.org/news/2017/01/update-us-abandons-
controversial-consent-proposal-using-human-research-samples [https://perma.cc/MY5D-BXP8]. Some 
view the outcome though as an inevitable consequence of disparate lobbying power between powerful 
research institutions and patient advocacy groups. Id. 
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for medical and scientific discovery.139 Allowing the current collection and 
usage practices of these samples to remain in effect allows the research com-
munity to utilize advances in genetic and genomic technologies to develop 
treatments, diagnostic tools, and personalized medical and health care from 
which all members of society can benefit.140 The passage of the updated regu-
lations, although still subject to revision or alteration prior to their implementa-
tion, counter the potentially harmful consequences of the burgeoning biorights 
movement.141 
The updated regulations, however, do not go far enough to ensure the 
continued advancement and progress of scientific and medical research and to 
help realize the tremendous promise of personalized medicine.142 This Part 
argues that additional legislative and regulatory action is needed to ensure the 
realization of such promise.143 Specifically, legislative action is needed to pro-
scribe the ability of an individual to contribute their biological material for re-
search purposes in exchange for compensation.144 Section A describes the con-
vergence of factors and developments that have created a potentially signifi-
cant impedance to the progress of scientific and medical research.145 Addition-
ally, the Section describes how the current legal and regulatory framework 
provides no adequate recourse to address this problem.146 Section B presents 
the strongest counter-arguments and considerations against the proscription of 
receiving compensation for biological material contributed for research pur-
poses.147 Finally, Section C argues that public policy considerations ultimately 
justify the suggested legislative action.148 
                                                                                                                           
 139 Id. The proposed change would have imposed significant costs on research institutions in 
setting up processes that facilitated obtaining consent during clinical care, as well as additional sys-
tems that tracked the consent data. Id. Additionally, there was concern that creating a link between the 
biosamples and consent forms created enhanced privacy risks. Id. Such concerns, however, overlook a 
much larger privacy risk inherent in the collection of a large number of biosamples and the sophistica-
tion of genetic sequencing technologies. Dry et al., supra note 51. A biosample that has been exten-
sively sequenced can be identifiable regardless of how many patient identifiers are removed. Id. 
 140 See Kaiser, supra note 138 (stressing the concerns of the biomedical research community that 
the proposed regulations would inhibit scientific and medical research); F. Randy Vogenberg et al., 
Personalized Medicine Part I: Evolution and Development into Therapeutics, 35 PHARMACY & 
THERAPEUTICS 560, 560 (2010) (describing how precision medicine can tailor medical therapy to 
provide the most effective effect in a safe manner ensuring better patient care). 
 141 Kaiser, supra note 138. 
 142 See infra notes 149–219 and accompanying text. 
 143 See infra notes 149–219 and accompanying text. 
 144 See infra notes 149–219 and accompanying text. 
 145 See infra notes 149–178 and accompanying text. 
 146 See infra notes 149–178 and accompanying text. 
 147 See infra notes 179–189 and accompanying text. 
 148 See infra notes 190–219 and accompanying text. 
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A. People Will Increasingly Demand Compensation for Their Biosamples 
At present, individuals can refuse to allow their biological material to be 
used for research studies.149 Individuals have no obligation to participate in 
research projects and cannot be compelled to participate in research studies.150 
Consequently, much of the motivating force driving the donation of bi-
osamples is rooted in altruism and a societal encouragement to participate in 
research that could eventually benefit society at-large.151 The biosample collec-
tion systems currently in place also function quite purposefully with a level of 
opaqueness and outside people’s knowledge or recognition.152 For example, by 
allowing hospitals and medical centers to collect leftover biological material 
without requiring informed consent, collection practices often go unnoticed by 
patients.153 Additionally, current collection practices benefit from the imposing 
nature of the environment in which the samples are collected.154 Even if people 
were aware, for instance, that their biological material would be collected for 
research purposes following surgery, they might be disinclined to refuse to 
contribute their biological material given the imposing nature and imbalance of 
power inherent in interactions with medical and healthcare institutions.155 The 
current biosample collection system operates on trust in the altruistic nature of 
individuals and the research and medical community at-large, but such trust is 
being increasingly strained due to a variety of economic, political, and social 
factors.156 
                                                                                                                           
 149 Dry et al., supra note 51. 
 150 Id. 
 151 Hakimian & Korn, supra note 1, at 2503. 
 152 See id. (cautioning that people’s altruism could be tempered by knowledge of commercial 
benefit). 
 153 See Michelle Meyer, No, Donating Your Leftover Tissue to Research Is Not Like Letting Some-




rifle-through-your-phone/] (describing how by informing people that their leftover biological material 
may be used for research, there is a greater risk of them not allowing the samples to be donated). 
 154 Id. 
 155 See Brian McKinstry, Paternalism and the Doctor-Patient Relationship in General Practice, 
340 BRIT. J. GEN. PRAC. 342, 342 (1992) (describing how issues of paternalism are common in medi-
cal practice and influence patient and doctor relationships and decision making); Meyer, supra note 
153 (noting how patients are often unaware of the consequences of donating biological material for 
research purposes and are susceptible to participating or refusing to participate based on incomplete or 
insufficient knowledge). 
 156 Hakimian & Korn, supra note 1, at 2503; see Robert J. Blendon et al., Public Trust in Physi-
cians—U.S. Medicine in International Perspective, 371 NEW ENG. J. MED. 1570, 1572 (2014) (de-
scribing that despite how the rising cost of healthcare has weakened people’s trust in the healthcare 
system, people largely still trust their doctors and other medical practitioners). Public sentiment to-
ward the pharmaceutical and biotechnology industry is quite negative, particularly with the skyrocket-
ing costs of prescription drugs, medical devices, and diagnostic tests. Jim Norman, Americans’ Views 
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Although there has not been a recorded, marked increase in people refus-
ing to contribute their biological material absent compensation, it is clear that 
people are less inclined to do so when they know financial or commercial gain 
is accruing to parties who utilize their material.157 Additionally, the emergence 
and accessibility of personal genetic testing has created the opportunity for 
people to know whether they carry any unique or scientifically valuable genet-
ic signatures.158 For instance, the public has never before been so easily and 
inexpensively able to discover if they have a rare genetic mutation that would 
be valuable to the biomedical research community.159 Through utilizing per-
                                                                                                                           
of Pharmaceutical Industry Take a Tumble, GALLUP (Sept. 14, 2015), http://www.gallup.com/poll/
185432/americans-views-pharmaceutical-industry-tumble.aspx [https://perma.cc/FQ7F-E34V]. There 
is undoubtedly going to be growing unease as genomic technologies are incorporated into people’s 
lives. See Lena H. Sun, Employees Who Decline Genetic Testing Could Face Penalties Under Pro-
posed Bill, WASH. POST (Mar. 11, 2016), https://www.washingtonpost.com/news/to-your-health/wp/
2017/03/11/employees-who-decline-genetic-testing-could-face-penalities-under-proposed-bill/?utm_
term=.b208b0ffa2e7 [https://perma.cc/37PA-AAR5] (describing a bill recently introduced in Congress 
that would allow employers access to people’s personal genomic profiles as part of workplace well-
ness programs). If employees refused to contribute that information, employers could penalize em-
ployees with charges of up to thirty percent of the total cost of the employee’s health insurance. Id. 
The proposed legislation has been highly criticized by a number of consumer, health, and medical 
advocacy groups, but the legislation represents the unease that can be cultivated as genomic technolo-
gies become more mainstream. Id. 
 157 Daley & Cranley, supra note 5. Survey evidence demonstrates that people are less inclined to 
help researchers when they know that researchers stand to recognize a commercial gain from their 
contributions. Id. Approximately 68% percent of people are willing to let researchers use their bi-
osample for any purpose. Id. When people know that their sample could be used to develop patents 
and generate monetary gain for commercial enterprises, however, support declines to 55%. Id. This is 
of particular concern given the increasingly close relationships and arrangements between nonprofit 
academic medical centers and for-profit biotechnology, pharmaceutical, and health data institutions. 
Deborah Josefson, Human Tissue for Sale: What Are the Costs?, 173 W. J. MED. 302, 303 (2000). 
Academic hospitals, for instance, have long been sending leftover pathology specimens to biotechnol-
ogy companies. Id. Although hospitals routinely stored clinically rare tumor tissues, for instance, 
those tissues were frequently analyzed in-house or shared within the hospital or other research institu-
tions. Id. Legal, financial, and ethical issues are now raised when such samples are used to directly 
increase a hospital’s revenue by selling such samples to for-profit institutions. Id. 
 158 Lee, supra note 6. By proving a simple saliva sample, personal genetic testing kits offer tre-
mendous insight into one’s family history and health risk profile. Peter Pitts, The Privacy Delusions of 
Genetic Testing, FORBES (Feb. 15, 2017), https://www.forbes.com/sites/realspin/2017/02/15/the-
privacy-delusions-of-genetic-testing/#26a94a5b1bba [https://web.archive.org/web/20180210190420/
https://www.forbes.com/sites/realspin/2017/02/15/the-privacy-delusions-of-genetic-testing/]. Global 
sales of genetic testing are expected to reach $10 billion. Id. Direct-to-consumer companies, like 
23andMe and Genos, are experiencing substantial consumer interest, selling tens of thousands at-
home testing kits every year. Id. The worldwide genetic testing market is estimated to expand from 
$4.6 billion in 2017 to $5.8 billion in 2022. Sramana Mitra, Billion-Dollar Unicorns: 23andMe in 
High Gear, SEEKING ALPHA (Dec. 5, 2017), https://seekingalpha.com/article/4129881-billion-dollar-
unicorns-23andme-high-gear [https://perma.cc/SS7Q-AHRX]. Such growth is fueled by an aging popula-
tion, increased awareness and incidences of genetic diseases, and technological advancements. Id. 
 159 Pitts, supra note 158. For instance, 23andMe has sold access to its database to at least thirteen 
outside pharmaceutical firms. Id. One buyer, Genentech, paid $10 million for the genetic profiles of 
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sonal genetic testing services, individuals can obtain access to their genetic 
information by simply mailing away a saliva sample.160 With the advent of 
genetic sequencing technology and the greater accessibility of personal genetic 
testing, people can more readily know if they harbor either a protective or 
pathogenic genetic variation that would be of significant research or commer-
cial value.161 We are currently in the early stages of the convergence of an in-
dividual’s ability to know if they harbor a genetically valuable and potentially 
lucrative mutation with a demonstrated societal unwillingness to contribute 
such material absent compensation if others stand to economically benefit.162 
                                                                                                                           
people suffering from Parkinson’s disease. Id. Another prominent player in this space, AncestryDNA, 
recently announced a lucrative data-sharing partnership with the biotechnology company Calico. Id. 
 160 Sarah Buhr, Genetics Startup Genos Wants to Pay You for Your DNA Data, TECHCRUNCH 
(Nov. 1, 2016), https://techcrunch.com/2016/11/01/genetics-startup-genos-wants-to-pay-you-for-your-
dna-data/ [https://perma.cc/Y56T-ZB52]. At present, direct-to-consumer genetics companies like 
23andMe, Genos, Color Genomics, Helix, and Veritas will provide exome sequencing of your DNA 
for as little as $199. Id. Exome sequencing is not as intensive as whole genome or next-generation 
sequencing, as it only covers what are referred to as the “protein coding genes.” Id. Exome sequencing 
is still useful in discovering diseases caused by rare genetic variants. Id. As next-generation sequenc-
ing is adopted more uniformly across the industry, individuals will have a more thorough understand-
ing of their genetic map, which researchers could use to better understand, prevent, and treat disease. 
Id. 
 161 Personal Genomics: The Future of Healthcare?, YOURGENOME.ORG, http://www.yourgenome.
org/stories/personal-genomics-the-future-of-healthcare [https://perma.cc/XYS6-8LK3]. A complaint was 
recently filed in U.S. District Court of Nevada by a couple who developed a drug to treat a rare neuro-
logical disease that they claim was improperly misappropriated by a drug developer. Complaint and 
Demand for Jury at 2, Hempel v. Cydan Dev., Inc., No. 18-cv-00008 (D. Nev. Jan. 5, 2018). The 
couple’s twin daughters suffered from Niemann-Pick disease, Type C (“NPC”), a rare, progressive, 
and fatal neurological genetic disease. Id. Spurred by their daughters’ illness, the couple, relying on $3 
million of their personal funds, outside donations, and pro-bono expertise by physicians, developed a 
treatment for the disease, which was granted preliminary approval by the FDA, as well as “Orphan 
Drug Status” which provided certain exclusivity rights for developers. Id. at 2–3. The couple alleged 
breach of contract and fiduciary duty claims, among others, by drug developer Cydan which used 
confidential information shared by the couple to develop a competing drug. Id. at 4–5. Of note, how-
ever, is that the complaint specifically alleges that given the only five-hundred known cases of NPC 
worldwide and the one-hundred in the United States, the twins “are the only known identical twins in 
the world living with NPC, making their medical information highly valuable.” Id. at 2. 
 162 See Christina Farr, Should You Get Paid for Your DNA, FAST COMPANY (Mar. 12, 2016), 
https://www.fastcompany.com/3057732/should-you-get-paid-for-your-dna [https://perma.cc/GS3G-
23BF] (describing how the development of a class of promising cholesterol lowering drugs known as 
PCSK9 inhibitors was catalyzed by the discovery of two patients who carried an extremely rare genet-
ic mutation that resulted in them having exceedingly low cholesterol levels). Clinical trials of this 
recently discovered class of drugs are promising and could be quite profitable for pharmaceutical 
companies. Id. According to Gregory Curfman, MD, Editor-in-Chief of Harvard Health Publications: 
“Every so often a medical advance comes along that rewrites the script for treating a disease or condi-
tion. After today’s announcements of impressive results of a new type of cholesterol-lowering drug, 
that scenario might just happen in the next few years.” Gregory Curfman, PCSK9 Inhibitors: A Major 
Advance in Cholesterol Lowering Drug Therapy, HARV. HEALTH PUB. (Mar. 15, 2015), http://www.
health.harvard.edu/blog/pcsk9-inhibitors-a-major-advance-in-cholesterol-lowering-drug-therapy-2015
03157801 [https://perma.cc/NQC4-VELP]. Such an approach to drug development—finding people 
who are impervious to heart disease for instance—is a significant advancement and “can open a door 
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Although there has not been, as of yet, a marked increase in people refusing to 
contribute their biological material absent compensation, it is unlikely the sta-
tus quo can be maintained into the foreseeable future.163 
The most analogous situation to selling one’s biological material for re-
search purposes is the sale of bone marrow or plasma.164 In Flynn v. Holder, 
the Ninth Circuit narrowed the definition of bone marrow in the Transplant Act 
to permit the sale of marrow, recognizing that modern technologies made the 
process easier and less risky.165 Doing so is demonstrative of a societal indica-
tion that we are not completely opposed to paying people for their biological 
material, absent the strong disapproval towards the most pronounced forms of 
organ trafficking and harvesting.166 It is also not an overly forward assertion 
that the market for blood donation could be quite robust if not for the fact that 
likely purchasers of the blood have adopted industry wide practices and inter-
nal policies that prevent the market from developing.167 By looking to the 
                                                                                                                           
to letting the rest of the population share their genetic luck.” Gina Kolata, Rare Gene Mutations In-
spire New Heart Drugs, N.Y. TIMES (May 24, 2017), https://www.nytimes.com/2017/05/24/health/
heart-drugs-gene-mutations.html [https://web.archive.org/web/20170827071444/https://www.nytimes.
com/2017/05/24/health/heart-drugs-gene-mutations.html]. 
 163 See Farr, supra note 162 (noting the emergence and increasing popularity of personal genetic 
testing services). New private-sector models are increasingly demonstrating the monetary value of 
one’s DNA. Id. Direct-to-consumer genetics companies, like 23andMe, operate by selling people’s 
health data to pharmaceutical companies in bulk. Id. One such arrangement between 23andMe and 
pharmaceutical company, Genentech, involved analyzing genetic data from three thousand 23andMe 
customers with Parkinson’s disease in order to identify genes that Genentech could use to then devel-
op drugs to treat the neurodegenerative disorder. Francie Diep, 23andMe to Sell Customers’ Genetic 
Data to Biotech Company, POPULAR SCI. (Jan. 7, 2015), http://www.popsci.com/23andme-inks-deal-
sell-customers-genetic-data-biotech-company [https://perma.cc/2QNY-87QQ?type=image]. The ar-
rangement may be worth up to $50 million according to some reports. Id. 23andMe is reported to have 
sold more than two million of its at-home testing kits. Mitra, supra note 158. 23andMe’s growth is 
particularly noteworthy; the eleven-year-old company is valued as high as $1.75 billion. Id. 23andMe’s 
growth is even more spectacular given that the company was ordered by the FDA in 2013 to stop 
selling its genetic health tests. Id. But, in 2015, the FDA authorized the company to market its tests for 
detecting a genetic variant associated with Bloom syndrome, a rare disorder associated with increased 
cancer risk. Id. In April 2017, the FDA authorized the company to market a test for ten genetic diseas-
es including Alzheimer’s and Parkinson’s diseases. Id. 
 164 See infra notes 165–170 and accompanying text. 
 165 684 F.3d 852, 857 (9th Cir. 2012). 
 166 Id. at 861. 
 167 See Preston, supra note 124 (explaining how hospitals and other medical providers refuse to 
use blood from paid donors out of concern that compensation encourages people to lie about their 
health and risk behaviors, thereby increasing the possibility of using contaminated or infected blood); 
Deborah Zabarenko, The Nation Has A Major Blood Shortage, ABC NEWS (Sept. 19, 2016), http://
abcnews.go.com/Health/story?id=117954&page=1 [https://perma.cc/T6AZ-5DJM] (describing how 
the Red Cross and America’s Blood Centers, which represent the vast majority of U.S. blood banks, 
routinely report shortages that require emergency appeals to the public). In situations such as these, it 
is likely that a market-based solution to the problem would entail providing compensation to prospec-
tive donors. Zabarenko, supra. A recent crisis was so severe that thirty-two of the Red Cross’s thirty-
six regions had less than a day’s supply of blood available or an inadequate supply to meet hospital 
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plasma donation market, it becomes clear that such a market could similarly 
develop for blood donation.168 Selling one’s biological material for research 
purposes could operate in a similar manner to the plasma or bone marrow mar-
ket.169 It is unlikely that researchers would suddenly begin to refuse to utilize 
scientifically valuable materials just because they were acquired in exchange 
for compensation, a situation distinct from that of blood donations.170 
The relevant regulatory framework, including the proposed regulations 
set to go into effect in 2018, are silent as to the issue of compensation for bio-
logical materials contributed for research purposes.171 The current legal 
framework for the sale of other types of biological materials also offers no 
mechanism to prevent the sale of biological material for research purposes.172 
Therefore, action needs to be taken to amend the Transplant Act to include 
a provision that expressly proscribes the ability of an individual to sell their bio-
logical material for research purposes.173 Action on the administrative agency 
level, such as amending the Common Rule, is insufficient as it would fail to pre-
vent the types of actions that are currently taking in place, such as people selling 
their biological materials to private companies that might not be governed by the 
Common Rule.174 This proposal would allow current collection practices to con-
                                                                                                                           
demand. Id. The Red Cross needs eighty thousand units on hand daily, but during this crisis, it had 
only about thirty-six thousand. Id. 
 168 See Wellington, supra note 131 (describing how there is an established market for compensa-
tion for contributing blood plasma, as there is a substantially reduced risk of contamination and infec-
tion when the plasma is used to make pharmaceuticals). 
 169 See id. (noting the robust market for blood plasma compensation to donors). 
 170 See Preston, supra note 124 (noting that there is not a concern of researchers to receive infect-
ed blood samples as the blood will not be transfused into another individual and researchers are more 
concerned with the genetic markers contained in the blood). 
 171 See Final Rule, supra note 98 (leaving unaddressed the issue of compensation for biosample 
contribution). 
 172 See, e.g., 42 U.S.C. § 274e(a)–(c) (2012) (omitting from the Transplant Act any proscription 
against providing compensation for biosamples contributed for research purposes). 
 173 Id. It would be difficult to amend the definition of “human organ” under the Transplant Act to 
include biosamples used for research purposes as the Transplant Act is concerned with “human trans-
plantation,” rather than research purposes. Id. § 247e(a). An amendment to the Transplant Act, how-
ever, could specifically proscribe the ability of individuals to receive “valuable consideration” for the 
contribution of biological material for research purposes. See id. § 247e(c)1(2) (defining valuable 
consideration as “not include[ing] the reasonable payments associated with the removal, transporta-
tion, implantation, processing, preservation, quality control, and storage of a human organ or the ex-
penses of travel, housing, and lost wages incurred by the donor”). 
 174 See 45 C.F.R. § 46.101(a) (2016) (stating that the Common Rule “applies to all research in-
volving human subjects conducted, supported or otherwise subject to regulation by any federal de-
partment or agency which takes appropriate administrative action to make the policy applicable to 
such research”). A private organization, such as DNASimple, is not a federal agency and might not be 
the recipient of federal funding; therefore, it might not be subject to the Common Rule. Id.; see supra 
note 5 and accompanying text (describing DNASimple’s business model and operational practices). It 
is possible, however, that such a private organization would likely fall under the purview of the 
Common Rule as such an organization might be performing research “otherwise subject to regulation 
by any federal department.” 45 C.F.R. § 46.101(a); see id. § 46.102(e) (describing “[r]esearch subject 
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tinue unchanged, in that hospitals or other research institutions could still collect 
de-identified biosamples collected during the course of clinical care without ob-
taining consent.175 Given that the proposal only addresses providing compensa-
tion for research, not therapeutic or clinical, purposes, it would also allow cur-
rent practices regarding bone marrow, blood, and plasma donation to go un-
changed.176 The current system could operate in such a manner as that of blood 
donations to blood banks with the addition of a law that specifically proscribes 
the exchange of monetary compensation.177 The nuances of such a proposal are 
beyond the scope of this Note, but I offer the outline of a legislative solution to a 
potentially harmful practice while causing the least amount of disruption as pos-
sible to the current legal and regulatory framework.178 
B. Is That Even A Problem? Shouldn’t People Be Encouraged to  
Seek Compensation for What Is Theirs? 
A common argument advanced in support of the proposition that people 
are rightfully entitled to compensation for their genetically valuable biological 
material is one rooted in some sense of equity or fairness.179 It seems facially 
unfair to allow researchers, biotechnology or pharmaceuticals companies, or 
even hospitals to financially profit from that which is derived from the indi-
                                                                                                                           
to regulation” as “encompass[ing] those research activities for which a federal department or agency 
has specific responsibility for regulating as a research activity (for example, Investigational New Drug 
requirements administered by the [FDA]”)); supra note 163 (describing how direct-to-consumer ge-
netics company, 23andMe, is subject to regulation by the FDA). 
 175 See 45 C.F.R. § 46.102(e) (stating that informed consent is not needed when researchers ob-
tain de-identified patient information or when there is no intervention or interaction with the individu-
al for research purposes). My proposal would also prevent the exchange of compensation for bi-
osamples even when informed consent is not required. Id. 
 176 See supra notes 114–121 and accompanying text (examining how current practices regarding 
bone marrow donation are the consequence of judicial reinterpretation of “bone marrow” under the 
Transplant Act which governs organ donation or transplantation). Given that my proposal is focused 
on the donation of biological materials for research purposes, rather than clinical or therapeutic pur-
poses, the current practice regarding bone marrow, blood, and plasma are unaltered by my proposal. 
See supra notes 122–125 and accompanying text (describing the process of donating blood to blood 
banks for clinical or therapeutic purposes); supra notes 126–133 and accompanying text (describing 
how plasma donations are used for the manufacture of pharmaceutical products). 
 177 See supra notes 122–125 and accompanying text (describing the process of donating blood to 
blood banks and the industry practice of not accepting blood from paid donors despite there being no 
regulation preventing such a practice); infra notes 202–203 and accompanying text (describing how 
nominal forms of compensation, such as gift cards or coupons, can provide a sufficient incentive to 
donate biosamples, as is the current practice for altruistic blood donation). 
 178 See supra notes 173–177 and accompanying text. 
 179 Farr, supra note 162. As DNA becomes more monetarily valuable as a revenue-producing 
commodity, many patient advocates are calling for a portion of that revenue. Id. According to Sharon 
Terry, founder and CEO of Genetic Alliance, a nonprofit organization that advocates on behalf of 
people with genetic diseases: “I think there may be an economy emerging in which we might want to 
include donors in the commerce that is taking place around clinical recruitment.” Id. 
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vidual.180 Physicians, for instance, are typically compensated for recruiting 
people into clinical trials and other research projects.181 If not for the individual, 
research and scientific discoveries and their resultant commercial applications 
would never have materialized.182 Those individuals are deserving of some form 
of compensation or equity in the resulting commercial application.183 
Such arguments have been strengthened in recent years by a number of 
high-profile incidents that have generated public discussion on the matter.184 
Of note has been the media coverage of the story of Henrietta Lacks.185 In 
1951, Lacks, an impoverished, African American mother of five, died of cervi-
cal cancer and her cells, unbeknownst to her or her family, were used to create 
the HeLa cell line, which has subsequently generated billions of dollars in eco-
nomic activity and is credited for fueling a proliferation of medical and scien-
tific discoveries over the past decades.186 In 2013, Lacks’ descendants formed 
an agreement with the National Institutes of Health (NIH) that would require 
researchers to apply for and obtain permission to use Lacks’ genomic data.187 
Two members of the Lacks family will be required to serve on the NIH panel 
responsible for reviewing such applications and any resulting publications 
should acknowledge the Lacks family.188 Although issues of compensation 
were not part of the considerations between the NIH and the Lacks family, the 
situation prompted a broader societal discussion of what people should be enti-
                                                                                                                           
 180 Id. 
 181 Id. 
 182 Id. 
 183 Id. The assertion that such individuals should be compensated for contributing their biological 
material is strengthened by the massive revenues drug companies derive from the resultant therapies. 
See Baumann, supra note 14 (noting that Spark’s Luxturna blindness gene therapy costs $850,000 for 
both eyes); Grady, supra note 14 (noting that Novartis’ Kymriah cancer gene therapy will cost 
$475,000); Kolata, supra note 12 (noting that Merck’s Keytruda cancer drug costs $156,000 a year). 
 184 Art Caplan, NIH Finally Makes Good with Henrietta Lacks’ Family—and It’s About Time, 
Ethicist Says, NBC NEWS (Aug. 7, 2013), http://www.nbcnews.com/health/nih-finally-makes-good-
henrietta-lacks-family-its-about-time-6C10867941 [https://perma.cc/5WKP-FUH3]. 
 185 Id. In April 2017, Home Box Office released “The Immortal Life of Henrietta Lacks,” a movie 
about the life and legacy of Henrietta Lacks and her cells, capitalizing on the success of a 2010 non-
fiction bestseller of the same name. Neil Genzlinger, Review: ‘The Immortal Life of Henrietta Lacks,’ 
Condensed, N.Y. TIMES (Apr. 20, 2017), https://www.nytimes.com/2017/04/20/arts/television/review-
the-immortal-life-of-henrietta-lacks-condensed.html?_r=0 [https://perma.cc/TL25-G5C9]. 
 186 Sarah Zielinski, Henrietta Lacks’ ‘Immortal’ Cells, SMITHSONIAN MAG. (Jan. 22, 2010), http://
www.smithsonianmag.com/science-nature/henrietta-lacks-immortal-cells-6421299/ [https://perma.cc/
VUF9-PQUM]. Lacks, an impoverished black tobacco farmer from Virginia was being treated for 
cervical cancer at John Hopkins University Hospital. Id. The cells were taken from a cervical biopsy 
performed on her and eventually used to create the HeLa cell line, the first immortal human cell line 
that was later used to create the polio vaccine and responsible for a variety of other scientific discover-
ies. Id. Lacks never knew her cells were being used for research and never consented to as much. Id. 
The family never received any profits derived from the creation of the cell line. Id. 
 187 Caplan, supra note 184. 
 188 Id. 
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tled to for their participation in socially valuable, but also commercially lucra-
tive, medical and scientific research.189 
C. Strong Public Policy Justifications Warrant the Proscription of 
Compensation for Biosamples Donated for Research Purposes 
A societal willingness to allow payment for an individual’s biological ma-
terial for research purposes poses a significant problem in the era of precision 
medicine and genomic research.190 Consequently, legislative action needs to be 
taken that makes it illegal for an individual to contribute his or her biological 
material for research purposes in exchange for monetary compensation.191 In a 
somewhat prophetic opinion, Justice Mosk advanced the position in his dissent 
in Moore v. Regents of University of California that the legislature could create 
a system that prevents the problems inherent in providing compensation for 
human biological material for research purposes.192 The policy justifications 
for such an action are robust.193 
If an individual is unwilling to donate his or her biological material absent 
compensation, potentially valuable information from which all of society could 
benefit is removed from the public repository of knowledge, thereby hamper-
ing societal progress.194 In economic terms, such a situation presents a classic 
tragedy of the commons dilemma.195 The absence of any regulation both fails 
to cure, and in some respects facilitates, a free-rider problem.196 Those who 
                                                                                                                           
 189 Id. 
 190 Meyer, supra note 153. 
 191 Id. 
 192 793 P.2d 479, 505–06 (1990) (Mosk, J., dissenting). In his dissent in Moore, Justice Mosk stated: 
It is certainly arguable that, as a matter of policy or morality, it would be wiser to pro-
hibit any private individual or entity from profiting from the fortuitous value that ad-
heres in a part of a human body, and instead to require all valuable excised body parts 
to be deposited in a public depository which would make such materials freely availa-
ble to all scientists for the betterment of society as a whole. The Legislature, if it 
wished, could create such a system, as it has done with respect to organs that are donat-
ed for transplantation. 
Id. 
 193 See infra notes 194–219 and accompanying text. 
 194 See Garrett Hardin, The Tragedy of the Commons, 162 SCIENCE 1243, 1248 (1968) (describ-
ing how society can suffer from an unwavering emphasis on personal liberty at the expense of broader 
societal benefit). All of society should be able to benefit from the genetic diversity within the human 
population. Id. By creating a system where individuals withhold their unique and scientifically helpful 
genetic material, all of society is worse off than if such information was shared freely and openly. Id. 
 195 Id. Although Hardin’s original paper addressed the issue of overpopulation, the concept has 
been extended to a variety of fields, including economics. Id. 
 196 See The Free Rider Problem, STAN. ENCYCLOPEDIA PHIL., https://plato.stanford.edu/entries/
free-rider/ [https://perma.cc/C6NP-GPN2] (recognizing that society as a whole benefits when individ-
uals participate in research projects that advance scientific understanding, individuals are less incen-
tivized to contribute if they know they will reap the benefits regardless of their participation). 
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possess valuable genetic information and are unable to receive what they per-
ceive as the appropriate compensation amount may ultimately fail to contribute 
their biological material.197 Those individuals will still benefit from those who 
are willing to contribute their biological material absent compensation.198 
Because of long-standing and well-founded mistrust of the medical re-
search enterprise, minority communities might be particularly unwilling to 
contribute their biological material without receiving some form of compensa-
tion.199 Such unwillingness could have the effect of increasing the cost of re-
search and potentially slowing its progress as minority communities can afford 
great insight into human genetic complexity and could demand high levels of 
compensation.200 The fulfillment of the promise of genomic medicine requires 
significant sample sizes of people with a variety of racial and ethnic profiles 
and backgrounds.201 Compensation in the form of nominal amount gift cards, 
coupons, or simple merchandise, as is currently offered to encourage altruistic 
blood donation, can serve as sufficient incentives to donate for research pur-
poses.202 The relative ease of donating a small amount of blood or saliva for a 
                                                                                                                           
 197 See id. (refusing to accept what is deemed an inferior offer of compensation harms society as 
valuable information is removed from the public knowledge). 
 198 See id. (minimizing the downside of refusing to contribute). 
 199 Spector-Bagdady, supra note 17. The recent public attention surrounding the story of Henrietta 
Lacks does not strengthen a sense of trust in the research community despite the long-overdue resolution 
of the matter in the eyes of the research community and the Lacks family. Caplan, supra note 184. 
 200 See Plunkett et al., supra note 109 (recognizing the significant risk that failing to achieve ge-
netic samples from a range of ancestries and ethnicities); see also Steph Yin, In South Asian Social 
Castes, a Living Lab for Genetic Disease, N.Y. TIMES (July 17, 2017), https://www.nytimes.com/
2017/07/17/health/india-south-asia-castes-genetics-diseases.html [https://web.archive.org/web/2017
0728124009/https://www.nytimes.com/2017/07/17/health/india-south-asia-castes-genetics-diseases.
html] (describing how certain genetically isolated South Asian populations, for instance, provide great 
insight to rare and common disease as well as basic biology). Populations with long histories of re-
striction of gene flow obtained largely by limiting marriages to within a limited group evidence what 
scientists refer to as a founder effect. Yin, supra. Isolated groups from India and Finland, for instance, 
as well as Ashkenazi Jews and the Amish, derived from a small group of founders that then bred only 
with each other. Id. Consequently, genetic variants within these groups become amplified and the rate 
of recessive genetic diseases is higher in offspring. Id. Scientists typically utilize animal models in 
which a disease carrying gene is rendered inoperative or “knocked out” to study the effect of the gene 
loss. A. Mesut Erzurumluoglu et al., Importance of Genetic Studies in Consanguineous Populations 
for the Characterization of Novel Human Gene Functions, 80 ANNALS HUM. GENETICS 187, 187 
(2016). These genetically isolated populations afford scientists the ability to study natural human 
“knockouts,” with scientists speculating that knockouts of every gene in the genome exists in India. 
Yin, supra. 
 201 Spector-Bagdady, supra note 17. 
 202 Id. Many in the genetic research community believe that patients should be compensated for 
their nominal travel expenses but nothing more. Farr, supra note 162. According to medical geneticist 
Robert Green of Harvard Medical School, academic medical centers should instead improve their 
outreach programs so that more people will volunteer their data; he argues that offering patients seri-
ous compensation would be an act of manipulation. Id. From a practical standpoint, offering compen-
sation to those with rare genetic mutations is straightforward. Id. But, there are still thousands of peo-
ple whose genetic data needs to be studied in order to make the comparison necessary to determine if 
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research study is not as labor intensive a process as an hours-long procedure to 
donate bone marrow or as demanding on the body as plasma donation.203 
In addition to the need for a robust and diverse cohort of genetic profiles, 
the promise of genomic medicine also requires a level of flexibility in investi-
gating different types of clinical conditions and diseases.204 The interrelated-
ness of different genetic markers and how they cause or prevent disease means 
that researchers need to have flexibility to explore potentially promising con-
nections and relations between genes and disease, some of which science has 
yet to fully understand.205 It would, therefore, be administratively burdensome 
and ultimately harmful to the progress of research to have people enter into 
compensation arrangements that only authorize researchers to use their biolog-
ical material for the study of a specific disease.206 Although broad consent to 
any research use could theoretically be obtained as part of an arrangement, the 
possibility that people would only provide a biosample for a narrow purpose 
would increase the costs of research, given the administrative costs of manag-
ing such requests, and slow its progress.207 
From a less practical standpoint, the sale of parts of one’s physical body, 
or in this instance the physical properties of one’s body, offends basic notions 
                                                                                                                           
a genetic profile is indeed rare. Id. Those thousands of people also need to be compensated in some 
fashion, as without them the individual with the rare genetic variant would never be able to command 
serious compensation. Id. Additionally, research ventures and commercial applications often fail, 
which presents a dilemma of having patients then having to partake in any downside risk as part of 
potential compensation arrangements. Id. 
 203 Wellington, supra note 131. 
 204 See M.B. Kapp, Ethical and Legal Issues in Research Involving Human Subjects: Do You 
Want a Piece of Me?, 59 J. CLINICAL PATHOLOGY 335, 336 (2006). A supposition of human genetic 
research is the complexity of the genetic links of even common diseases. Id. For complex diseases, 
there is an even more tremendous need for large amounts of genetic and clinical data. Id. Researchers 
need to use genetic material to investigate linkages between different diseases in order to work most 
effectively. Id. 
 205 Id. 
 206 Id. 
 207 Id. The costs of drug development are already staggering, with the average cost to develop and 
gain marketing approval for a new drug an estimated $2.6 billion. Tufts CSDD Assessment of Cost to 
Develop and Win Marketing Approval for a New Drug Now Published, TUFTS CTR. FOR STUDY DRUG 
DEV. (Mar. 10, 2016), http://csdd.tufts.edu/news/complete_story/tufts_csdd_rd_cost_study_now_
published [https://web.archive.org/web/20180323180828/http://csdd.tufts.edu/news/complete_story/
tufts_csdd_rd_cost_study_now_published]. But see Gina Kolata, What Does It Cost to Create a Can-
cer Drug? Less Than You’d Think, N.Y. TIMES (Sept. 11, 2017), https://www.nytimes.com/2017/
09/11/health/cancer-drug-costs.html [https://perma.cc/WL8K-D5M9] (describing the findings of a 
recent study that peg the drug development cost at $757 million). Critics of the study point to its lim-
ited sample size of ten cancer medications all developed by relatively small companies with “only one 
drug approved, with few other drugs of any type of development.” Id. Such a selection bias, critics 
argues, fails to account for the fact that 95% percent of cancer drugs that enter clinical trials ultimately 
fail, and any cost estimates need to include these failed attempts. Id. 
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of human dignity and respect.208 There is a shared national aversion to the ex-
ploitation of one’s body for economic gain.209 The dignity and sanctity with 
which we regard the human body is offended when we begin to pay people for 
that which is so fundamental to their very identity.210 Additionally, failing to 
proscribe compensation for biosample contributions for research purposes 
would create a pricing system or market for each individual.211 The human 
body should be beyond pricing, and we do not want this pricing to be conduct-
ed by the private market.212 Looking to how the Transplant Act made the sale 
of organs illegal, the use of consideration in exchange for biological material 
would offend societal and personal values.213 
The proscription of offering compensation for the contribution of biologi-
cal material for research purposes is rooted in numerous public policy justifica-
tions.214 Such a seemingly significant change to the current legal framework 
                                                                                                                           
 208 Moore, 793 P.2d at 497–98 (Arabian, J., concurring). The plaintiff in Moore, by asking the 
court to enforce a right to his body tissue for profit, is entreating the court “to regard the human ves-
sel, the single most venerated and protected subject in any civilized society, as equal with the basest 
commercial commodity. He asks us to commingle the sacred with the profane.” Id. 
 209 Id. Justice Arabian, later in his opinion, lauds dissenting Justice Mosk who wrote that, “our 
society acknowledges a profound ethical imperative to respect the human body as the physical and 
temporal exposition of the unique human persona.” Id. Justice Arabian interpreted such a statement as 
leading to a contrary conclusion of the issue stressing, “Does it uplift or degrade the unique human 
persona to treat human tissue as a fungible article of commerce?” Id. 
 210 Id. 
 211 GUIDO CALABRESI & PHILIP BOBBITT, TRAGIC CHOICES 92–98 (1978). In a non-tragic con-
text, society often allows allocation decisions to market mechanisms. Id. at 31. Society allows indi-
viduals to act as the principal actors and choosers and to make decisions to further their goals without 
any overt coercion or centralized planning. Id. Such a system raises concerns when it is applied to 
situations like being able to buy out of a wartime draft or to auction off cancer chemotherapy to the 
highest bidder. Id. In such situations, there is what the authors refer to as the problem of “costs of 
costing.” Id. at 32. The market is to assign costs to certain goods and bads, which is needed in order 
for society to make any market-based allocation decisions. Id. There are external costs, such as moral-
ism and the affront to certain societal values, to make the value of a life reducible to a monetary fig-
ure. Id. 
 212 Id. at 32. Having the market, in this case the medical and healthcare enterprise, dictate the value 
of one’s body offends notions of human dignity and respect. Id. Even if such a determination can be 
made, there are also external costs that all of society must bear by having one’s body assigned a monetary 
value. Id. There is little reason to suspect that the private market would not seek to value certain individ-
uals and their genetic uniqueness. See Kolata, supra note 12 (describing how only 4% of cancer patients 
have the genetic variant that is treatable with Merck’s Keytruda cancer drug, but that there would still be 
60,000 U.S. patients each year who would be candidates for the $156,000 per year drug therapy); Rob 
Stein, FDA Approves First Gene Therapy for Leukemia, NAT’L PUB. RADIO (Aug. 30, 2017), 
https://www.npr.org/sections/health-shots/2017/08/30/547293551/fda-approves-first-gene-therapy-
treatment-for-cancer [https://perma.cc/PUS6-3D3L] (estimating that are 3100 patients diagnosed each 
year with the type of leukemia that is treatable with Novartis’s $475,000 Kymriah gene therapy). 
 213 CALABRESI & BOBBITT, supra note 211, at 32. 
 214 See, e.g., id. at 92–98 (describing how pricing what is most fundamental to our identities of-
fends societal notions of dignity and respect for human life). 
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governing biomedical research is also not unprecedented.215 Public policy justi-
fications have supported the determination that an individual’s ownership rights 
to his or her tissues are extinguished once the tissue leaves the body.216 Policy 
justifications have also supported the determination that consent is not needed 
for the use of de-identified samples.217 Furthermore, the Supreme Court’s 2013 
decision in Association for Medical Pathologists v. Myriad Genetics is broadly 
demonstrative of a desire to encourage research and scientific discovery and not 
lock up valuable information from which society at large can benefit.218 Legisla-
tive action, or amending the Transplant Act in particular, to prevent individuals 
from receiving compensation for contributing their biological material for re-
search purposes is supported by numerous public policy justifications.219 
CONCLUSION 
Swift and targeted legislative action needs to be taken that proscribes the 
exchange of compensation for contributing one’s biological material for re-
search purposes. There is a strong public policy vein throughout the judicial 
and legislative framework guiding modern human subject research that seeks 
to encourage access to and use of biosamples. The stakes are too high with the 
advent of precision medicine and the significant advances being made almost 
daily in the field to have such progress stifled in any manner, especially by 
having the research community engage in costly, time consuming, and compli-
cated processes of paying individuals for their biological material. Further-
more, having to engage in this type of pricing of the most fundamental aspects 
of personhood offends our shared notions of human dignity and respect. 
MARK A. HAYDEN 
                                                                                                                           
 215 See, e.g., Moore, 793 P.2d at 493–95 (holding that individuals do not retain an ownership 
interest in their cells after the cells are removed from their bodies). 
 216 Id. 
 217 Kaiser, supra note 128. 
 218 See Ass’n for Med. Pathologists v. Myriad Genetics, 569 U.S. 576, 580 (2013) (holding that 
naturally occurring human genes are not patentable as they are a product of nature and not patent 
eligible just because they have been isolated). 
 219 See, e.g., Kaiser, supra note 128 (warning of the risk to the progress of scientific and medical 
discoveries posed by impeding researchers’ access to the samples they need). 
